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Abstract 
Obstructive sleep apnea (OSA) is a common public health concern in many 
countries, including Portugal, causing deleterious effects on metabolic and 
cardiovascular health. There are still, however, gaps in scientific and clinical knowledge 
in this field.  
Continuous positive airway pressure (CPAP) is considered the first line treatment 
in OSA, reducing co-morbidities and associated societal consequences such as 
accidents and cognitive impairment. However, residual sleepiness may persist in some 
patients and most chronic consequences of OSA may not be fully reversed by CPAP 
treatment. Therefore, studies are needed to estimate the reversible effects of CPAP 
(differences pre- to post-CPAP treatment) and irreversible effects of OSA, in other 
words, estimate the difference between patients with non-treated OSA and patients 
after effective treatment, when compared to controls. 
The objective of this study was to evaluate, using a proteomic approach, the 
molecular effect of the therapeutic benefit and/or side effects of continuous positive 
airway pressure treatment in red blood cells of OSA patients with comorbidities, 
namely diabetes. Notwithstanding the focus on RBCs, plasma samples were also 
further analyzed to make the results more robust. 
The results of the study have shown that PRDX2 is highly modulated in OSA 
patients with or without diabetes, and is associated with OSA’s severity and metabolic 
status. We reported higher hyperoxidation of RBC PRDX2 oligomeric forms in diabetic 
OSA patients, and also higher hyperoxidation of plasma PRDX2 and PRX 1/4 in this 
same group.  
CPAP benefits, including glycemic control, may correlate with RBC PRDX2 
oligomeric redox-state associated with chaperone activity, and with decrease of 
plasma PRDXs stress-induced inflammation pathways. 
PRDX2 is a promising biomarker candidate for OSA severity and metabolic status. 
 
 
  
Key words: OSA-induced hypoxia, PRDX2, redox modulation, glycemic control, CPAP.  
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Resumo 
O Síndrome da Apneia Obstrutiva do Sono (SAOS) é um problema de saúde 
pública emergente, comum em muitos países, incluindo Portugal. Esta doença é 
caracterizada por um colapso das vias aéreas superiores durante o sono, que provoca a 
diminuição ou interrupção do fluxo de ar, normalmente seguido de um despertar do 
sono. Como consequência, os pacientes sofrem de fragmentação do sono e sonolência 
diurna excessiva, tendo inúmeras repercussões no dia-a-dia.  Além destas, a SAOS 
pode originar complicações graves, de natureza cardiovascular e metabólica. Entre 
outras complicações pode-se salientar hipertensão arterial, hipertensão pulmonar, 
insuficiência respiratória, arritmias e acidentes vasculares cerebrais. Os principais 
factores de risco para esta doença são a idade, obesidade, género, consumo de  álcool 
e tabagismo. 
Além de um distúrbio grave do sono, a SAOS é também uma doença de stress 
oxidativo. O stresse oxidativo surge quando ocorre uma diminuição da capacidade 
antioxidante, e um excesso de produção de espécies reactivas de oxigénio e/ou de 
nitrogénio. Apesar de os radicais livres possuírem um papel importante na regulação 
de vias de sinalização fundamentais para inúmeras funções celulares, quando há 
excesso de produção destas formas reactivas, estas podem causar danos em lípidos, 
proteínas e ácidos nucleicos, afectando diversos mecanismos celulares e fisiológicos. 
Assim, os repetidos eventos apneicos caracterizados pela hipóxia intermitente 
induzida pela SAOS estão na base de danos moleculares que, ao longo dos anos, 
podem revelar-se irreversíveis. 
Existem várias medidas terapêuticas para a SAOS, contudo o tratamento de 
eleição é o CPAP (do inglês Continuous Positive Airway Pressure). Este método consiste 
na aplicação de uma pressão aérea positiva contínua por um ventilador, que é 
transmitida ao paciente através de uma máscara nasal, mantendo a via aérea 
permeável e permitindo um fluxo aéreo contínuo. 
A utilização do CPAP possibilita uma melhoria clínica imediata, quando usado 
regularmente, melhorando assim a qualidade de vida dos pacientes. No entanto, as 
consequências crónicas derivadas da SAOS podem não ser totalmente revertidas pelo 
tratamento com CPAP. Assim, é importante compreender os mecanismos moleculares 
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que estão na base da SAOS, para poder melhor compreender os benefícios do CPAP, 
que podem contribuir para o desenvolvimento de novas terapias para esta doença. 
Os glóbulos vermelhos, sendo as células responsáveis pelo transporte de 
oxigénio às diferentes regiões e órgãos do corpo, são considerados uma fonte de 
inflamação sistémica que pode conduzir a doenças metabólicas, tais como obesidade, 
resistência à insulina e hipertensão, patologias reconhecidas como inerentes à SAOS.  
Estudos recentenmente desenvolvidos do Laboratório de Proteómica do INSARJ 
tiveram como objectivo analisar o proteoma de glóbulos vermelhos em doentes com 
SAOS, bem como os efeitos moleculares do CPAP nos glóbulos vermelhos destes 
doentes, com o intuito de encontrar potenciais biomarcadores para diagnóstico e/ou 
monitorização da doença. Foi reportado pelos autores que diversas proteínas se 
encontravam diferencialmente expressas nos doentes com SAOS e após o tratamento 
CPAP, sendo a Peroxirredoxina II (PRDX2) uma das consideradas mais relevantes para o 
estudo.  
A PRDX2 é a terceira proteína mais abundante nos glóbulos vermelhos, sendo 
por isso fundamental para a sua sobrevivência. As PRDXs possuem funções 
importantes na célula. Além da sua função peroxidática, que ajuda a combater stress 
oxidativo através da degradação do peróxido de hidrogénio, actuam em vias de 
transdução de sinal, e possuem também actividade chaperone, dependendo da sua 
estrutura redox-oligomérica, sendo por isso importantes na protecção dos glóbulos 
vermelhos contra stresse oxidativo. 
Estudos desenvolvidos no Laboratório de Proteómica do INSARJ anteriormente 
mencionados, mostraram que as formas monomérica e dimérica desta enzima 
antioxidante PRDX2 se encontravam significativamente hiperoxidadas nos glóbulos 
vermelhos de doentes com SAOS, principalmente durante a manhã, sugerindo a 
presença de stresse oxidativo severo que por sua vez leva a uma homeostasia 
antioxidante alterada, nos glóbulos vermelhos destes pacientes. Seis meses de 
tratamento com CPAP diminuíram esta hiperoxidação e originaram formas 
multiméricas hiperoxidadas, associadas à função chaperone da PRDX2, e descritas 
como estruturas protetoras que ajudam a aumentar a resistência ao stresse celular. Os 
níveis de PRDX2 oxidada correlacionaram-se com parâmetros polisomnográficos e 
metabólicos, nesses pacientes. Portanto, o estado redox / oligomérico da PRDX2 nos 
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glóbulos vermelhos tem sido proposto por esses autores como promissor candidato a 
biomarcador para gravidade da SAOS e monitorização do tratamento. 
Assim, o objetivo deste trabalho consiste na validação da PRDX2 como potencial 
biomarcador, tendo como alvo de estudo, além da SAOS, a comorbidade diabetes, e os 
efeitos moleculares do tratamento CPAP nos glóbulos vermelhos destes pacientes. 
Para este efeito decidimos usar um cohort maior do que o utilizado nos estudos 
anteriores, composto por um grupo controlo (n = 18 em que dois são diabéticos), um 
grupo de pacientes SAOS não tratados (n = 18 em que três são diabéticos), e o mesmo 
grupo de doentes SAOS após seis meses de tratamento CPAP. 
Os resultados deste estudo corroboram com os anteriores.  Verificou-se que, no 
geral, a  hiperoxidação da PRDX2 nos glóbulos vermelhos é mais elevada em pacientes 
SAOS, e diminui após seis meses de tratamento CPAP. Contudo, isto só acontece em 
pacientes SAOS não diabéticos. Após seis meses de tratamento CPAP, os pacientes 
SAOS com diabetes não revelam uma diminuição da hiperoxidação da PRDX2. Além 
disto, verificou-se o aparecimento de formas multiméricas hiperoxidadas após o 
tratamento CPAP, principalmente em pacientes não diabéticos. Estudos de correlação 
revelaram que os níveis de formas monoméricas e diméricas da PRDX2 correlacionam 
positivamente com prarâmetros do sono, nomeadamente RDI, ODI, T90, enquanto as 
formas multiméricas hiperoxidadas correlacionam positivamente com parâmetros 
metabólicos como a glicémia e hemoglobina glicada, sugerindo que na presença de 
hipóxia induzida pela SAOS não tratada, estes pacientes podem ter menor capacidade 
de produzir estruturas multiméricas potetoras na resposta a um aumento de níveis de 
glucose no sangue, capacidade que pode ser recuperada com o tratamento CPAP.  
Analisando estes resultados, considerámos pertinente fazer uma experiência 
semelhante em amostras de plasma, utilzando o mesmo cohort, para robustecer o 
estudo da PRDX2 nestes doentes. O estudo revelou formas oligoméricas diferente das 
encontradas nos glóbulos vermelhos. Contudo, o estado oligomérico da enzima 
corrobora com os resultados anteriores: há um amento da quantidade de PRDX 2 em 
pacientes com SAOS, com ou sem diabetes,  e uma diminuição após seis meses de 
tratamento CPAP, sendo que  esta diminuição é significativa em pacientes não 
diabéticos. Além disto verificámos que os níveis das formas hiperoxidadas 
correlacionam positivamente com parâmetros relativos ao metabolismo glicolítico 
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como glicémia, hemoglobina glicada e HOMA-IR. Após o tratamento CPAP estas 
correlações deixaram de se verificar, excluindo o grupo de pacientes SAOS com 
diabetes, que as manteve.  
Assim, podemos dizer que o estado redox/oligomérico da PRDX2 pode ser 
considerado um potencial biomarcador para a severidade da SAOS e controlo do 
tratamento CPAP. Contudo, será necessário recorrer a outro tipo de abordagens que 
permitam estudar a fundo a PRDX2, nomeadamente as modificações pós traducionais 
desta enzima, e a sua relação com a SAOS e parâmetros metabólicos dos pacientes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Palavras-chave: Hipóxia induzida pela SAOS, PRDX2, modulações redox, metabolismo 
glicolítico, CPAP. 
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* Note - The boxed scheme represents the work carried out in this thesis project 
Highlights 
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 CPAP benefits, including glycemic control, may correlate with RBC’s PRDX2 
oligomeric state associated with chaperone activity, and with a decrease of 
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1 Introduction  
Obstructive sleep apnea (OSA) is a common public health disease, inducing 
nocuous effects on metabolic and cardiovascular health, being thus intimately related 
to major consequences as arterial hypertension (AHT), stroke and diabetes. The 
continuous positive airway pressure (CPAP) is considered to be the most successful 
therapy for OSA, reducing associated co-morbidities and societal consequences. 
However, chronic consequences of OSA may not be fully reversed by CPAP treatment. 
Therefore, studies are needed in order to better understand metabolic changes 
associated to OSA, and to analyze CPAP’s efficiency on these patients. The present 
thesis is focused on identifying means by which OSA can be identified and monitored. 
A proteomic approach was used to assess the molecular effect of the therapeutic 
benefit and/or side effects of CPAP treatment in red blood cells and plasma of OSA 
patients with comorbidities, namely diabetes. The thesis work targets a potential 
candidate biomarker – Peroxiredoxin II – reported as a promising marker for OSA 
severity and/or treatment monitoring.  In the introduction a general overview of the 
disease is given followed by a brief consideration about biomarkers and then a more 
detailed description of proteomics and Peroxiredoxin II as a protein biomarker for OSA.   
1.1 Obstructive Sleep Apnea  
Obstructive sleep apnea (OSA) is a sleep disorder characterized by recurrent 
episodes of upper airway collapse during sleep. There is an incomplete obstruction of 
the pharynx during sleep, which causes cessation (apnea) or significant decrease 
(hypopnea) in airflow, in the presence of breathing effort 1. OSA can be defined as a 
decrease in the oro-nasal airflow of at least 50% and at least 10 seconds, generally 
associated with reduced levels of arterial O2 and increased blood levels of CO2 
2. These 
episodes of airway obstruction are usually followed by arousals. As a consequence, of 
OSA, patients have sleep fragmentation and excessive daytime sleepiness 3.  
Hypopnea is defined as a 50 to 80% reduction in airflow, and originates from 
similar mechanisms to those that produce apnea. It may result in a reduction in 
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respiratory efforts due to a partial obstruction of the upper airway, and can also lead 
to increased blood levels of CO2 and reduced levels of arterial O2.  
Snoring is also a form of partial airway obstruction, which results from a flow 
restriction and an increase in respiratory efforts, and just like apnea and hypopnea, 
leads to hypoventilation and/or sleep arousal 4.  
The apnea/hypopnea index (AHI) describes the total number of apnea/hypopnea 
episodes per hour of sleep, which is usually <5 in normal individuals. The severity of 
OSA is indicated by AHI scores of 5–15 for mild, 15–30 for moderate and >30 for 
severe, and patients are characterized accordingly 5 as shown in table 1.1.  
 
Table 1.1: Apnea/Hypopnea Index6 
Mild 5 to 15 events per hour 
Moderate 15 to 30 events per hour 
Severe More than 30 events per hour 
1.2 Etiology and Pathogenesis 
Sleep and its interaction with the respiratory control system destabilize the 
capacity of the upper airway to drive air into the lungs 4. The loss of muscle tone 
promotes upper airway collapse during sleep, causing intermittent hypoxia, 
hypercapnia, sympathetic nervous system activation, and arousal from sleep 7. 
Among the causes of apneic events, we may highlight a reduced excitatory 
stimulation, an active suppression of breathing due to inhibitory reflexes (coming 
either from the cardiovascular system, lungs and chest wall, or other somatic and 
visceral afferents), and loss of reflexes which normally ensure the maintenance of 
ventilation and do not rely on chemical control. Airway patency can also be 
compromised by a small or posterior placed mandible, redundant soft palate, tonsillar 
hypertrophy, and pharyngeal fat deposition. The recurrent apnea results from the 
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instability of the respiration feedback control, which causes the venting to occur in 
cycles, rather than remaining at a constant level 4,7.  
The respiratory efforts against the obstruction cause large increases in cerebral 
blood flow and in blood pressure, since it increases the cardiac output 4.  
It has been shown that sleep-disordered breathing is associated with daytime 
hypertension, so other pathogenic mechanisms must be active. For example, obesity 
causes pharyngeal fat deposition, which is a major factor. Increased SNS (Sympathetic 
Nervous System) activity, insulin resistance, systemic inflammation, altered oxidative 
stress and endothelial dysfunction are also factors that promote daytime 
hypertension, and are, therefore, intimately related to OSA’s pathogenic mechanisms7. 
1.3 Epidemiology 
Despite spending about a third of our lives asleep, it is only recently that the 
impact of the physiological state on breathing began to be better known. In fact, only 
in the 70s did the term " sleep apnea syndrome " emerge 8. 
Obstructive sleep apnea is widely recognized as a major public health concern 
with numerous societal consequences, such as increased cardiovascular morbidity, 
heightened risk for metabolic dysfunction, and behavioral and cognitive deficits 
leading to impaired work performance and productivity 5,9. The overall incidence is 
approximately 2% to 4%, with a predominance of males from 2:1 to 4:1. The 
prevalence of OSA varies widely, ranging from 14.7% to 36.5%, depending on gender 
and nationality. OSA also creates a huge economic burden when compared to other 
chronic diseases 9. 
1.3.1 Risk Factors 
The most common risk factors for OSA are: obesity, age over 50 and a neck 
circumference of more than 41 cm for females and more than 43 cm in males 10. 
Gender, ethnicity, craniofacial abnormalities, genetic factors, as well as alcohol and 
smoking, are also important risk factors to be considered in OSA patients 11. 
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1.3.1.1 Age and Gender 
Several epidemiologic studies show that more than 50% of adults over the age of 
65 have some form of chronic sleep-related complaint. This is, in part, due to the 
variability in sleep parameters, being related with the high prevalence of OSA in 
advanced ages 11.  An early study reported that 70% of men and 56% of women aged  
between 65 and 99, had obstructive sleep apnea defined as an AHI ≥ 10 events per 
hour 12.  
Despite OSA being  more common in men than women, it is still not clear why 13. 
In men, obstructive sleep apnea (AHI>10 events/h) is present in 3.2% of 20 to 44 year 
olds, 11.3% in 45  to 64 year olds, and 18.1%  of those in the 61  to 100 years old age 
group. On the other hand, in women, the prevalence of OSA (AHI > 15 events/h) is 
0.6% in ages of 20 to 44 years, 2.0% in 45 to 64 years, and 7.0% in groups of 61 to 100 
years old 14,15.  Since men and women are anatomically different, this prevalence could 
be attributed to anatomical and functional properties of the upper airways, which 
might cause different responses in the ventilatory effort and/or arousals from sleep. 
For instance, imaging studies have revealed that men have increased fat deposition 
around pharyngeal airway when compared with women 13.  
Also, hormonal differences play a role in the predisposition to abnormal 
breathing during sleep, and may help to explain the high prevalence of OSA in men, 
and women’s susceptibility in the post- menopausal phase, to also develop this 
disease11,13. 
1.3.1.2 Obesity 
Body weight has been identified as the major risk factor for obstructive sleep 
apnea by many epidemiologic studies around the world. More than 60% of patients 
referred for a diagnostic sleep evaluation exhibit, excessive body weight 11,16. It is 
known that an increase in body weight may lead to the development of moderate to 
severe OSA, accelerating the progression of the disease 11. For instance, fat deposition 
around the abdomen often leads to a reduction of the residual capacity. A reduced 
lung volume causes tethering effects on the upper airways, since it is associated with 
diminished oxygen stores, which may contribute to ventilator control instability. 
Finally, obesity has been associated with functional deterioration of the upper airway 
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muscles, also caused by fat deposition around the neck, which induces a reduction in 
functional residual capacity with a resultant decrease of the caudal traction on the 
upper airway 16. 
Body weight is a critical factor, since the pathophysiology of OSA is directly linked 
with obesity, with an estimated 58% of moderate to severe cases being caused by a 
BMI greater than or equal to 25 kg/m2. In order to minimize the current epidemic of 
obesity and, consequently, OSA, it is fundamental to find effective strategies to 
achieve long-term and sustainable weight loss along with life quality improvement 11. 
1.3.1.3 Genetic and Anatomical factors 
Studies using linkage analysis have provided a potential association between 
specific areas of the genome and OSA pathogenesis, also showing a common 
hereditary basis to the development of OSA, regardless of whether the patient is obese 
or not 16. Still, no causative gene for OSA has been identified until now, but work is 
underway. Symptoms regarding apnea and the number of apneas per hour of sleep are 
present at a frequency twice as higher in families with affected members than in 
control families combined by age, gender and socio-economic level 17. 
However, differences in craniofacial morphology may explain some of the 
changes in the risk of obstructive sleep apnea, in different ethnic groups 11. 
Craniofacial dimorphism is associated with a subsequent positioning of the tongue 
base, which restricts the upper airways 18. 
1.3.1.4 Smoking and drinking habits 
Smoking and drinking habits have been suggested as possible risk factors for 
OSA11. Current smoking habits are associated with a higher prevalence of snoring and 
sleep-disordered breathing, and may also worsen the degree of these breathing 
disorders, when compared with those who have never smoked 13. Even exposure to 
second-hand smoke has been independently linked with habitual snoring 11. This can 
be explained by cigarette-induced airway inflammation and damage changing the 
structural and neural properties of the upper airway, increasing thus the risk of 
collapsibility during sleep 11,13.  On the other hand, alcohol relaxes upper airway dilator 
muscles, which can prolong apnea duration and worsen the hypoxemia severity. 
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Alcohol consumption may also suppress arousals and increase the frequency of 
occlusive episodes. However, the underlying mechanisms are still not well understood 
13.  
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1.4 Symptoms 
Symptoms for OSA include snoring, excessive daytime fatigue, apneas while 
sleeping, morning headaches, concentration problems, forgetfulness, depression, and 
sexual dysfunction, among others associated with metabolic disturbances. OSA 
remains mostly undiagnosed, since patients only come to the attention of a clinician 
when they complain of daytime sleepiness, or when their bed partners witness apnea 
episodes 19. 
 Table 1.2: Nocturnal and daytime symptoms for Obstructive Sleep Apnea 8 
 
1.5 Consequences 
The recurrent episodes of apnea-hypopnea and arousals during sleep may cause 
a series of metabolic changes, leading to cardiovascular and neuronal problems, which 
will condition a significant increase in morbidity and possibly mortality 8.  
Nocturnal symptoms Daytime symptoms 
 
 Nonrestorative sleep  
 Frequent loud snoring 
 Witnessed apneas, which often 
interrupt the snoring 
 Gasping and choking sensations that 
arouse the patient from sleep 
 Nocturia 
 Insomnia 
 Restless sleep, with experience of 
frequent arousals and tossing or 
turning during the night 
 
 
 Morning headache 
 Dry or sore throat 
 Daytime fatigue/tiredness 
 Cognitive deficits; memory and 
intellectual impairment (short-term 
memory, concentration) 
 Decreased vigilance 
 Personality and mood changes, 
including depression and anxiety 
 Sexual dysfunction, including 
impotence and decreased libido 
 Gastroesophageal reflux 
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1.5.1 Arterial hypertension  
OSA’s association with AHT is frequent.  An estimated 30-50% of patients with 
hypertension have OSA, while 20- 70% of patients with OSA have hypertension. It is 
known that obesity and age are risk factors for hypertension, and as these factors are 
very often present in patients with OSA, AHT was initially attributed to obesity and 
age. However, recent studies have shown that age, obesity and OSA are independent 
and additive risk factors of hypertension.  
1.5.2 Heart function 
In OSA, cardiac output decreases during sleep. This is due to negative 
intrathoracic pressure during the episodes of apnea, which can be significantly 
improved with CPAP treatment. OSA alone does not seem to cause heart failure. 
However, some studies showed that OSA may be an important risk factor for the 
development and aggravation of ischemic heart disease. Also, HTA, hypoxia and 
increased sympathetic activity during sleep seem to accelerate atherosclerosis. On the 
other hand, in the presence of an ischemic heart disease, hypoxia caused by apneas 
may lead to ischemia and cause angina, myocardial infarction or severe arrhythmias. 
CPAP treatment was shown to improve ischemic cardiopathy 8. Essentially, ischemia, 
caused by hypoxia, might stimulate proteins which, in the presence of O2 (in 
reperfusion), may overproduce free radicals, which directly cause tissue damage20. 
1.5.3 Cerebrovascular diseases 
Patients with OSA have also increased morbidity and mortality of stroke. These 
patients cerebral blood flow decreases during sleep, whereas intracranial pressure 
increases in a cyclic manner, reaching its peak at the end of each apnea event.  
1.5.4 Pulmonary hypertension 
Pulmonary hypertension occurs in about 15% to 25% of patients with OSA. For 
PHT diagnosis, it is necessary to have a chronic respiratory failure due to a respiratory 
disease, most often Chronic Obstructive Pulmonary Disease (COPD) or major obesity 8. 
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1.6 Diagnosis 
Several associated features should suggest the diagnosis of obstructive apnea-
hypopnea sleep syndrome. 
Table 1.3: Features commonly associated with OSA, useful for diagnosis 17 
Features commonly associated with  
apnea-hypopnea obstructive syndrome sleep 
 Obesity 
 Mandibular/jaw hypoplasia 
 Systemic hypertension 
 Pulmonary hypertension 
 Tonsil hypertrophy  
 Sleep fragmentation 
 Sleep associated arrhythmias 
 Night angina 
 Gastroesophageal reflux 
 Compromised quality of life 
 
Routine laboratory tests, such as pulmonary function tests, thyroid function, 
blood gas analysis, echocardiography or chest X-ray, are generally not helpful in 
making the diagnosis.  Polysomnography is distinguished from sleep studies since it 
includes sleep staging, which is meant to include an Electroencephalogram (EEG), 
Electrooculogram (EOG), and a submental Electromyogram (EMG). Additional 
parameters of sleep include ECG, airflow,  ventilation and respiratory effort, gas 
exchange by oximetry, extremity muscle activity, motor activity-movement, extended 
EEG monitoring,  penile tumescence,  gastroesophageal monitoring, snoring, body 
positions, etc. 21 Given the various symptoms and signs, clinical aspects alone do not 
allow the prediction with certainty of which patients will or not have OSAs. Thus, the 
clinical aspect allows only the selection of which patients are indicated for a 
polysomnographic recording, and only these recordings can truly diagnose OSA. 
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1.7 Treatment 
Nasal continuous positive airway pressure (CPAP) therapy is undoubtedly the 
treatment of choice for symptomatic OSA patients and/or patients with associated 
heart or cerebrovascular diseases. However, despite its efficacy, treatment compliance 
is limited due to the side effects associated with the use of nasal CPAP and to the lack 
of perception of its benefit by affected individuals 22.   
CPAP is effective both for the treatment of long-term obstructive sleep apnea 
and for the prevention of snoring. The effects depend on the positive level of pressure 
applied on the respiratory system, as the ideal pressure levels differ among patients. 
Even if CPAP is suspended, its effects might last for days, so short interruptions 
of therapy for example, due to acute clinical diseases or even to have surgery, are well 
tolerated. However, some failures may occasionally occur: sometimes due to very low 
pressure, others due to an increase in the pressure required to prevent apnea. Factors 
such as alcohol consumption, hypothyroidism, and obesity can aggravate the stability 
of the airways.  
Generally, patients accept CPAP therapy very well. However, most studies 
indicate that some patients (approximately 30%) do not accept it as well 4. Side effects 
of the therapy may include a feeling of breathlessness, nasal dryness or rhinitis, ear 
pain and conjunctivitis. It is important to mention that CPAP’s beneficial effects are 
controversial. Most studies show CPAP contributes to restore an OSA patient’s health, 
by helping them reduce breathing efforts during the night, and this reduces daytime 
sleepiness and also improves the quality of life. On the other hand, OSA’s patients with 
other major comorbidities and metabolic problems may have trouble using CPAP 
treatment. This is a controversial matter still under discussion 23,24,25. Absolute 
contraindications to nasal CPAP therapy are complete nasal obstruction and fracture of 
the communicating skull base.  
Other options for OSA treatment can be considered, such as  intraoral devices, or 
even surgical interventions, depending on the causes underlying the disease 17.  
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1.8 Oxidative Stress and OSA 
In living cells, oxidation-reduction (redox) reactions are present in fundamental 
processes of redox regulation, named ‘redox signaling’ and ‘redox control’. Events like 
intermittent hypoxia often lead to a disturbance in this homeostatic balance, causing 
oxidative stress, and the consequent formation of reactive oxygen and nitrogen 
species (ROS/RNS) 26. As mentioned before, OSA is characterized by a repeated 
obstruction of the upper airways, during nighttime sleep 27, causing episodes of 
intermittent hypoxia, which over time may lead to tissue injury in areas such as the 
cardiac muscle, lung and brain tissues, among others, causing direct damage 20. 
Although several mechanisms are involved, such damage is mainly attributed to 
the production of reactive oxygen species (ROS) during re-oxygenation. These are 
highly reactive molecules, which interact with lipids, proteins, and nucleic acids, and as 
such, are responsible for the development of several pathologies 27,28. 
Even though they cause oxidative damage, these molecules play a major role in 
cell signaling mechanisms, acting as “redox switches”. For instance, ROS activate an 
inflammatory cascade, resulting in the increase of proinflammatory cytokines and the 
expression of adhesion molecules. Therefore, the exacerbated production of these 
reactive species may result in endothelial dysfunction and, thereby, cause the 
predisposition to several morbidities in patients with untreated OSA 29. 
For this reason, oxidative stress is now  considered a major contributor to the 
cardiovascular consequences observed in this group of patients 30. 
Red blood cells (RBCs) are particularly exposed to oxidative stress, mainly due to 
hemoglobin autoxidation and subsequent constant flux of superoxide (O2
-). Therefore, 
intraerythrocytic peroxidase activity is critically relevant, as it plays and important 
protective role against oxidative stress-induced damage 31.  
1.9 Comorbidities in study: Diabetes Mellitus 
Diabetes mellitus is an endocrine disease involving hormones, namely insulin, 
produced by the islets of Langerhans in the pancreas. This is a disease of great 
importance since at present it is a frequently seen disease, almost endemic, affecting 
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all countries worldwide, all ethnic groups and all social classes. The International 
Diabetes Federation (IDF) estimates that currently about 246 million people have 
diabetes worldwide, 46% of whom are aged between 40 and 50 years. By 2025, it is 
estimated that this number will increase up to 380 million. The most prevalent is type 
2 and it currently affects 5.9% of the world adult population, with almost 80% coming 
from developing countries. The IDF estimates the prevalence of diabetes in Portugal to 
be about 6-8%. 
Diabetes is considered an evolutionary disease affecting quality of life and life 
expectancy. Chronic complications caused by diabetes affect all organs and systems. It 
is considered the leading cause of blindness and renal failure in developed countries, 
and also the most important cause of lower limb amputations and heart and brain 
macrovascular disease. Neuropathy is another frequent complication which, together 
with the other outcomes, is highly disabling. The main cause of death in people with 
diabetes is cardiovascular complications (including stroke). About 3.8 million people 
die each year from diabetes, which is equivalent to the number of people dying from 
AIDS 32.  
1.10 Classification of Diabetes Mellitus 
The classification of Diabetes Mellitus adopted in Portugal is based on the 
standards published by the World Health Organization (WHO) in 1999, defining the 
classification of diabetes mellitus and other categories of glucose intolerance. 
Type 1 diabetes mellitus (T1DM) is a specific autoimmune disease of the 
pancreas. It can appear at any age, but is most common in the first decades of life, 
with a peak of incidence at 13-15 years. This form of diabetes occurs in about 5-10% of 
all people who suffer from diabetes. It is believed that there is a genetic predisposition 
and a precipitating factor for this type of diabetes to develop. This association results 
in the activation of various immune mechanisms leading to progressive autoimmune 
damage of the beta cells of the pancreatic islets, starting with a progressive decrease, 
until exhaustion, of insulin production 32. 
Type 2 diabetes mellitus (T2DM) is a heterogeneous disease that results from 
genetic, environmental and metabolic changes, which contribute to a key defect: 
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insulin resistance and compensatory, but insufficient, secretion of insulin by pancreatic 
beta cells 32.  
Concerning the cellular mechanisms of insulin resistance in type 2 diabetes, 
there is defective glycogen synthesis, as a consequence of multiple factors, such as the 
level of glucose transport (GLUT4), hexokinase II and glycogen synthetase activity. Also 
free fatty acids (FFA) play a key role in the induction of insulin resistance, in obesity 
and type 2 diabetes. Obesity and physical inactivity, which follow type 2 diabetes in 
over 80% of cases, are factors which worsen insulin resistance and are thus involved in 
the growing epidemics of type 2 diabetes. 
Signs and symptoms of type 2 diabetes result either from the lack of insulin or 
from the lack of its action, and include polyuria, polydipsia, polyphagia and weight loss. 
These classic signs may not be very obvious, and the disease might only be diagnosed 
late, through the manifestation of chronic complications.  
Type 2 diabetes can be prevented or delayed in people at risk (obese, elderly or 
with diabetic first-degree relatives). Prevention is based on an appropriate and 
continued exercise program, and a careful diet. Early diagnosis and timely effective 
treatment are crucial. Nowadays there are a set of oral drugs (oral antidiabetics) that 
can be used alone or in combination, in order to improve their efficiency. Insulin 
should also be used whenever oral drugs are unable to correct the disease. Since 
diabetes is often associated with hypertension and dyslipidemia, these changes must 
be treated in order to reduce cardiovascular risk 32. 
1.10.1 OSA and Type2-Diabetes 
OSA is common in people with type 2 diabetes. Given the high prevalence of OSA 
and type 2 diabetes in older adults, the presence of one of these conditions prompt 
the evaluation of the other, since up to 50% of patients with OSA have type 2 diabetes, 
and approximately 50% of patients with type 2 diabetes have moderate to severe OSA. 
It is known that as age increases, the predisposition for developing type 2 diabetes also 
increases, as there is a decrease in insulin sensitivity and insulin secretion by the 
pancreatic beta-cells. This is mainly attributed to fat accumulation and also a reduction 
in mitochondrial function in muscle 33. 
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Figure 1.1: Interactions between age, OSA and type 2 diabetes 33 
Age seems to be the main common factor behind both OSA and type 2 diabetes 
development (Figure 1.1). An increase in age is associated with impairments in sleep 
quality, and thus increase susceptibility to OSA. Also, it is more likely for older people 
to develop insulin resistance, glucose intolerance and type 2 diabetes, since 
intermittent hypoxia and sleep fragmentation play a fundamental role in its 
development 33.  The mechanisms through which intermittent hypoxia and sleep 
fragmentation may affect glucose metabolism are illustrated in figure 1.2. 
 
Figure 1.2: Association and causal links for OSA and metabolic abnormalities, leading to 
type 2 diabetes 33. 
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OSA may accelerate the age-related progression of glucose intolerance, which 
eventually leads to type 2 diabetes. Also, OSA may cause an increase in oxidative 
stress, as well as in the sympathetic nervous system activation, which can lead to a 
decrease in insulin sensitivity and secretion. 
OSA’s severity has, concomitantly, been associated with higher fasting glucose 
and glucose levels, reinforcing the idea that patients with OSA seem to have a higher 
prevalence of type 2 diabetes and metabolic syndrome. Surprisingly, some studies on 
CPAP treatment for OSA fail to demonstrate consistent improvements neither in 
metabolic function, nor in glycemic control. But it is important to notice that these 
studies may have methodological flaws such as small sample size, limited duration of 
treatment or even poor adherence to CPAP therapy, and are therefore conclusions 
concerning the metabolic effects of CPAP in OSA patients may require further 
investigation 33.  
1.11 Biomarkers Discovery 
The definition of a biomarker is a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacological response to therapeutic intervention (The Biomarker Definition 
Working Group, 2001).   
The term “biomarker” was first mentioned in 1973 by the journal Space Life 
Science, but its definition has suffered many alterations until 1980, when biomarkers 
were employed as a parameter to assess a given biological or clinical process. Still, an 
incorrect understanding of this definition often leads to ambiguity and its common 
misuse 34.  
Biomarkers are used daily in a clinical setting to assess disease diagnosis, 
prognosis and risk, as well as for monitoring therapeutic efficiency. For example, the 
diagnosis of diabetes is given through an evaluation of serum glucose levels, one of the 
most widely known examples of a clinical biomarker in use, nowadays. In a clinical 
perspective, biomarker refers to a broad subcategory of medical signs, which are 
characteristics of biological processes that  can be measured accurately and 
reproducibly 35.  
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Biomarkers can be placed in different categories, depending on their utility: 
diagnostic, early detection (screening), monitoring, prognostic, safety, and efficacy 
biomarkers 36. In regards to the stages of biomarker discovery and establishment, this 
is distinguished by three different ranges: exploratory biomarkers, probable valid 
biomarkers and known valid biomarkers 37. The process of biomarker development, 
i.e., discovery, validation, and regulatory approval, is a long, arduous and complex 
process. 
A wide range of technologies can be utilized for detection of biomarkers, 
including genomic, epigenomic, proteomic and metabolomic approaches 38. In the 
present thesis validation of a protein biomarker, Peroxiredoxin II, is described and so a 
more extensive consideration of this type of biomarker is now provided. In disease 
biomarker discovery, proteomics have been popular in blood, either in plasma, serum 
or blood cells. Despite proteomics technologies being in constant development, the 
most popular procedures are two-dimensional gel electrophoresis (2-D gel) and liquid 
chromatography (LC) for protein separation, both followed by tandem mass 
spectrometry (MS/MS) for protein identification 19. 
Proteomics refers to the set of technologies applied to explore the proteome, 
allowing evaluation of hundreds to thousands of proteins at specific timings and under 
specific conditions. A proteomics approach has innumerous advantages such as 
gathering information regarding changes in protein abundance, post-translational 
protein modifications (PTMs), as well as protein–protein cell and tissue interactions, 
which can be crucial to understanding the true molecular phenotype of a disease, and 
helping uncover disease biomarkers and disease targets for new drug development 19. 
1.11.1 Discovery phase 
The first stage of this study was an early biomarker discovery phase, in which 
RBC samples from OSA patients were analyzed by a 2D-DIGE based proteomic 
technique, followed by mass spectrometry, for protein identification and protein 
annotation and classification using bioinformatics tools 39. Results from this early study 
led to several proteins to be identified and noted as differentially expressed, one of 
which, PRDX2, will go through a rigorous validation phase. 
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1.12 Biomarker Validation  
Peroxiredoxin II has been reported to be a good candidate biomarker for OSA  
severity and treatment monitoring 39. However, further validation is required. Herein 
we will proceed for PRDX2 validation as candidate biomarker, regarding its association 
with OSA associated with comorbidities, namely diabetes, and also study CPAP’s 
molecular implications on these patients, to test its true efficiency.  
1.12.1 Biomarkers in OSA 
Previous studies reported several differentially expressed proteins in OSA 
patients, before and after CPAP treatment, one of which was PRDX2, and it was 
considered to be the most relevant for further validation as candidate biomarker for 
OSA severity and/or treatment monitoring 39.  
(PRDXs) are a large family of thiol-containing peroxidases. Their primary function 
relies on their peroxidase activity, which contributes to the control of endogenously 
produced peroxides, in eukaryotes 40. Besides their role in antioxidant activity, PRDXs 
are shown to be involved in other cellular functions, such as proliferation, 
differentiation 41, intracellular signaling 42, and chaperone activity 40, and have also 
been shown to play an important role in the circadian cycle 43. Mammalian cells 
express six PRDX isoforms, which can be found at several cellular compartments 41 – 
PRDX1, 2 and 6 can be found in the cytosol, PRDX3 in the mitochondrial matrix, PRDX4 
in the endoplasmic reticulum, and PRDX5 can be found in mitochondria, peroxisomes 
and in the cytosol 44.  In human erythrocytes, Peroxiredoxin II (PRDX2) is known to be 
the third most abundant protein 40.  
1.12.1.1 Peroxiredoxin II 
2-Cys Peroxiredoxins (PRDXs) are typically present as non-covalent homodimers 
with a disulfide formation bound between the peroxidatic cysteine of one monomer 
with the resolving cysteine of another monomer 44. 
Reduced PRDXs can be oxidized by a molecule of hydrogen peroxide that bind to 
their peroxidatic cysteine (SpH) sites, allowing the resolving cysteines (SrH) to form a 
disulfide bond (S-S) with them (Figures 1.3). 
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Figure 1.3: The peroxidatic cysteine (SpH) reacts with hydrogen peroxide to form a 
sulfenic acid.  The oxidized cyseine SpOH can then condense with the resolving 
cysteine (SrH) on the opposing PRDX to form a intermolecular disulfide bond 44. 
 
The thioredoxin system (Trx/NADPH) is responsible for reduction of the 2-Cys 
PRDXs. The reduction of the disulfide is considered to be the rate-limiting step in the 
PRDXs catalytic cycle, since both thioredoxin (Trx) and thioredoxin reductase are 
present at lower concentrations in cells than the PRDXs. Thereby, cells under oxidative 
stress are expected to intermediately accumulate oxidized PRDXs 44.  
A second oxidation may occur in the intermediate Sulfenic form of 2-Cys PRDXs. 
The sulfenic cysteine can be further oxidized by another hydrogen peroxide molecule, 
to a sulfinic form (S-SO2H). This sulfinic form can be recycled by the Srx/ATP cycle 
(Figure1.4). Sulfiredoxin (Srx) was found to bind to hyperoxidized PRDXs, making it 
possible to reduce hyperoxidized forms. However, this reduction is very slow. 
Hyperoxidized forms can still be present in the cell several hours after oxidative stress 
exposure, making it possible to detect by Western Blotting 43,44. Also, a further, but 
irreversible oxidation may occur, when another molecule of H2O2 reacts with the 
sulfinic cysteine (Cys-SO2H) of a PRDX, turning it into a sulfonic form (S-SO3H) (Figure 
1.4).This reaction effectively removes PRDX from the redox cycle43. 
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Figure 1.4: Adapted 44 Redox interconversions of typical 2-Cys PRDX, and their recycling 
cycles.   
In human cells, PRDX is in the form of a reduced and oxidized dimer, and can 
exchange subunits together, to form decamers or dodecamers. The hyperoxidation of 
PRDX interferes with these changes, causing the formation of hyperoxidized decameric 
molecules. These hyperoxidized structures can be converted into high molecular mass 
(oligomers and multimers) which are associated with increased chaperone activity 43. 
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Figure 1.5: Reduced PRDX can exist as decamers or dodecamers that dynamically 
exchange subunits with a cellular pool of oxidized and reduced dimers 43. 
PRDXs have a dynamic quaternary structure within the cell, thus each 
conformational state is thought to have its own functionality. For instance, as oxidized 
(S-S/S-S) PRDXs tend to stay in a decameric form, reduced, hyperoxidized or disulfide-
linked (S-S) PRDXs can adopt decameric or dodecameric structures. These reduced 
decameric structures seem to be the most stable, under physiological conditions. The 
dodecamers rapidly turn over, release oxidized dimers, which are quickly reduced, in 
order to re-enter the oligomeric state 43. 
However, when hyperoxidation into the sulfinic form occurs, this dynamic cycle 
could be frozen, which leads to the formation of larger complexes, like multimers, 
promoting functionality changes of PRDX within the cell (Figure 1.5).Therefore, as 
PRDX function changes according to different oligomeric forms, it is essential to study 
the oligomeric-redox state of these proteins, since post-translational modifications, 
such as hyperoxidation, may play a crucial role in oxidative stress-related molecular 
mechanisms. 
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The redox-oligomeric state of PRDX2 can be studied by non-reducing SDS-PAGE 
followed by Western Blotting (WB) with specific antibodies for PRDX2 and PRDX SO2/3, 
to evaluate the amount of oligomeric forms in different  reduced, oxidized and 
hyperoxidized  states. 
 
 
Figure 1.6: Adapted 39.  Measurement of PRDX2 redox/oligomeric states in RBC with 
NEM analyzed by SDS-PAGE under non-reducing condition followed by Western 
blotting with Ab-PRDX2 or Ab-PRDXSO2/3 
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In sample preparation, it is very important to add some sort of alkylating agent to 
help prevent external oxidation or re-oxidation (for example N-Ethylmaleimide – 
NEM). This compound binds to the dimer/monomer reduced cysteines, preventing 
external oxidations that naturally occur throughout the study process 44. 
All monomeric, dimeric and multimeric forms can be distinguished in different 
separated protein bands, each one with a different molecular mass, as shown in Figure 
1.6. By analyzing all these bands, each one corresponding to a specific protein form, 
we intend to unveil some answers about PRDX2 oxidation status, and its correlation 
with clinical and polysomnographic data, trying to understand how it might relate with 
OSA and OSA severity, with regards to the effects of CPAP treatment, in diabetic and 
non-diabetic patients.   
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2 Objective 
Recent studies 39 by INSARJ Proteomics Laboratory showed alterations in several 
proteins, mainly related with stress response and redox regulation, namely, PRDX2, in 
OSA patients. Previous validation assays confirmed that in the morning, monomeric 
and dimeric forms of PRDX2 were hyperoxidized in OSA RBCs when compared to 
evening samples. Also, after six months of CPAP treatment, these oligomeric PRDX2 
forms showed a significant decrease in dimer/monomer hyperoxidation, adding a 
multimeric form that is thought to be related to signaling and chaperone activities. 
Concerning the correlation between PRDX2 oligomeric forms and the patient’s clinical 
parameters, differences have been shown in insulin and insulin resistance, which were 
significantly higher in OSA patients than in snorers 39. 
Taking these results into account, the aim of this study endeavors to unveil the 
mechanisms behind the pathogenesis of OSA, and its relationship with the therapeutic 
response in patients with OSA, with a special emphasis on diabetic patients, as 
diabetes seems to be intimately linked with OSA severity. The aim was achieved 
through attainment of the following objectives: 
1) Analysis of redox-oligomeric forms of PRDX2 in Control and non-treated OSA 
groups, in diabetic and non-diabetic patients, both in RBCs and plasma; 
2) Analysis of redox-oligomeric forms of PRDX2 in OSA group after six months 
of CPAP treatment, in diabetic and non-diabetic patients, in both RBCs and 
plasma. 
3) Correlation of efficiency of CPAP treatment and the impact of diabetes on 
these patients’ health and metabolic status. 
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3 Material and Methods  
3.1 Samples and Patients 
A total of 104 patients with suspected OSA were clinically analyzed in the 
Department of Pulmonology, in order to create a set of medical records which collated 
demographic data, lifestyle, nutritional status, body mass index, blood pressure, heart 
rate, metabolic profile, and polysomnographic parameters (PSG) for each patient. All 
the data was further introduced into a database – Biobank. This database included 
only male patients, with ages between 25 and 55 years of age. 
The diagnosis was made by the polysomnographic exam. Before the PSG, 
patients underwent a restricted diet for three days. This exam was carried during the 
night, in a sleep laboratory. All these data are archived in a Database associated with a 
Biobank (plasma and erythrocytes) under informed consent, approved by the national 
data protection and Ethics Commission of the Northern Lisbon Hospital Center and by 
the National Institute of Health Dr. Ricardo Jorge. 
3.1.1 Sample selection 
In this study, three groups of individuals were selected from the Biobank: a group 
of 18 individuals without OSA (control group – snorers), in which two were diabetics, a 
second group of 18 individuals with OSA, in which three were diabetics and a third 
group of 18 individuals (same individual of the second group) after six month CPAP 
treatment, making a total of 54 different samples. Demographic, polysomnographic 
and analytical characterization for this cohort is shown in annex III. 
3.1.2 Sample preparation 
All stock samples (total 54), both RBCs and plasma needed to be previously 
prepped before running the gel. They were prepared using NEM (N- Ethylmaleimide) to 
prevent eventual external oxidation (Figure 3.1A and 3.1B).  The NEM solution was first 
prepared with ethanol (96%) to a final concentration of 2M, and from this solution we 
prepared another one, to a final concentration of 100mM, using a physiological saline 
solution (NaCl 0.9%). Sample preparation is described in Figure 3.1. 
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Figure 3.1: RBCs (A) and Plasma (B) sample preparation for WB. Preparation starts with 
sample dilution using NEM 100 mM and ethanol 96%, with addition of protease 
inhibitors. RBC and Plasma samples are further diluted with ultrapure water for total 
protein quantification. Diluted samples are then adjusted for specific total protein 
concentration for WB – 1:200 dilution is used in RBC sample adjustment for 70μG (A) 
and 1:10 dilution is used in Plasma sample adjustment for 40 μG total protein (B). 
3.1.3 Total protein quantification 
All the previously prepared samples were quantified by a colorimetric method – 
Thermo Scientific Pierce 660nm Protein Assay – which includes pre-diluted standards of 
bovine serum albumin (BSA) and a reagent which is responsible for color changing – 
Ionic Detergent Compatibility Reagent (IDCR). This is a quick and easy test to use for 
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total protein quantification and is more linear than coomassie-based Bradford assays, 
as it is compatible with higher concentrations of most detergents, reducing agents and 
other commonly used reagents.  
The samples were applied one to each microplate well, the reagent is then added 
and the microplate is stirred for five minutes, or until the color is uniform. The reading 
of the absorbance was performed in a spectrophotometer – Spectra max 340, 
Molecular Devices – at a wave-length reading of 660nm. Standards absorbance was 
used to provide a calibration curve, which then allows us to calculate the protein 
concentration of each sample simply by replacing the absorbance value in the line 
equation. It is important to note the need to dilute the stock samples to a 
concentration of 1:200 for RBCs and to 1:100 for plasma. This is absolutely necessary 
to assure that the absorbance values are in the range of the calibration curve values.  
From previous testing, it was decided to adjust the final concentration of RBCs 
samples to 70 μG, and plasma samples to 40 μG of total protein – results shown in 
annex II. 
3.2 Western Blotting  
3.2.1 1DE SDS-PAGE 
The nature of the samples used in this study makes them a complex mixture of 
proteins, thus it is necessary to separate the protein in the sample using their 
molecular weight. For this purpose, we used 1DE SDS-PAGE.  
SDS is an anionic detergent which contains molecules with a negative charge in a 
wide pH range when dissolved. This detergent destroys the complex structure of 
proteins (provokes denaturation) and binds to the polypeptide chains, giving them a 
negative charge. Thus, the negatively charged proteins only depend upon its molecular 
mass to move along the gel. All gels used in this study were NuPAGE 4-12% Bis-Tris 
Mini Gels (1.0mm x 15 well) – NOVEX by life Technologies.  
These precast gels are composed by two different layers, which have different 
functions. The first layer (stacking gel) is needed to concentrate all proteins in one 
band, allowing them to migrate at the same time. The second layer (running gel) 
effectively allows proteins to separate, according to their molecular weight. 
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3.2.2 Sample preparation for 1DE 
The previously prepared samples were adjusted to a final total protein 
concentration of 70 μG for RBCs (from 1:200 samples) and 40μG for plasma (from 1:10 
samples).  In order to homogenize the final volume for the race (10μL/lane), it was 
necessary to freeze-dry RBC samples using different volumes for each sample (see 
annex II). After lyophilization, it was added 2.5 μL LDS (Lithium Dodecyl Sulfate) of 
NuPAGE LDS Sample Buffer 4X NOVEX by Life Technologies, and 7.5 μL ultrapure water 
(type II) was added to each sample, followed by stirring at 70 ° C for 10 minutes, in 
order to denature the sample proteins. 
It was not necessary to freeze-dry plasma samples, since the volume needed to 
adjust for 40μG of total protein was less than 10 μL. In order to have a final volume of 
10L/lane, it was added 1,5 μL LDS and 1 μL β -mercaptoethanol – reduced conditions – 
it was added ultrapure water and 1:10 diluted plasma was added in different volumes 
for each sample (see annex II).  2 μL marker (Magic Mark XP Western Protein Standard, 
NOVEX by Life Technologies) was also applied to the gel. 
The electrophoretic run was performed under a potential of 150V, for 
approximately one hour, using a denaturing concentrated running buffer – NuPAGE® 
MES SDS Running Buffer (20X) – 30 mL of this buffer diluted in ultrapure water, to a final 
volume of 600 mL. 
3.2.3 Membrane Transfer 
After the proteins were separated by molecular weight, using SDS-PAGE, they 
were transferred from the gel to PVDF – polyvinylidene fluoride – membranes 
(Immobilon- P Membrane, PVDF, 0.45 μm, 26.5 cm x 3.75 m roll, for Western Blotting – 
Millipore, Fisher Scientific). PVDF membranes were pre-activated with 100% methanol 
(v/v) (Merck) for 15 minutes with some agitation, and then washed with ultrapure 
water, before they were incubated with complete transfer buffer (composition in 
annex I) for 10 minutes, with stirring. 
This is a wet transfer, meaning it occurs immersed in transfer buffer, at a low 
temperature. For this purpose, it was necessary to hold the gel next to the membrane, 
in constant contact with the buffer, pressured between sponges – in a sandwich. Thus, 
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the sandwiches were assembled in the following order: pad, 3MM papers, gel, 
membrane, 3MM papers and pad. Subsequently, the sandwiches were placed in a 
cuvette with transfer buffer, as shown in figure 3.2.  
 
Figure 3.2: Adapted  45. Electroblotting using a tank transfer unit. After the cassette is 
assembled (A) it is then placed in a tank containing transfer buffer (B). The membrane 
is positioned on the anode side of the gel and charged proteins are transferred from 
the gel onto the membrane.  
The 3MM papers and pads used to make pressure and increase contact between 
the gel and the membrane were also soaked in full transfer buffer. The transfer took 
place at 10 ° C for 1 hour and 30 minutes at 400 mA. 
3.2.4 Verification of protein transfer from SDS-PAGE gels to 
PVDF membranes 
After transference, the membranes were incubated in a 0.1% (p/v) Ponceau 
solution in 5% (v/v) acetic acid (composition in annex I) over five minutes with stirring, 
and then discolored for five minutes with 5% (v/v) acetic acid, in order to visualize the 
transferred protein bands. After reddening, the membranes were scanned, and the 
images obtained were stored for later analysis. This staining was then removed 
through several successive washings using PBS-T buffer 1x (Phosphate Buffered Saline 
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Tween20 solution – composition indicated in annex I) with vigorous stirring, until the 
dye was completely removed from the membranes. At this stage, the membranes 
were dried, between 3 MM papers, and vacuum stored at 4 ° C until use. 
3.2.5 Membrane Blocking 
To avoid non-specific binding (between antibody and membrane), the 
membranes were blocked with a solution of 5% (p/v) nonfat dry milk (Nestlé) diluted in 
PBS-T buffer, for 1 hour, with some stirring, at room temperature. 
3.2.6 Membrane incubation with primary antibody 
After the blocking stage the membranes were washed twice with PBS-T, and 
then incubated with a primary antibody (concentration used is shown in table), with 
slow stirring, overnight at 4 ° C. The antibodies used in this study were: Anti-
peroxiredoxin-2 (Ab-15572, rabbit polyclonal, Abcam) and Anti-peroxiredoxin-SO2/3 
(Ab-16830, Rabbit polyclonal, Abcam). All antibodies were diluted in a solution of 5% 
milk powder in PBS-T. 
3.2.7 Membrane incubation with secondary antibody 
After incubating the membranes with the primary antibody, a washing cycle was 
initiated with two brief washes, a 15 minutes wash and ending with three washings of 
5 minutes stirring with PBS-T buffer, to remove the excess primary antibody. 
The secondary antibody used was anti-rabbit IgG HRP (GE Healthcare, UK) which 
was also diluted in 5% (p/v) milk powder in 1x PBS-T (concentrations in Table 3.1). This 
incubation was performed for 1 hour with slow agitation, at room temperature. Then 
began a new washing cycle, identical to the primary antibody wash cycle, differing 
during the last 5 minutes of washing, where a 1x PBS solution (Phosphate Buffered 
Saline solution – composition in annex I) was used, instead of PBS-T buffer. 
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Table 3.1: Dilutions of primary and secondary antibodies used in this study. 
RBCs analysis Plasma analysis 
Antibodies Dilutions Antibodies Dilutions 
Anti-PRDX2 1:20000 Anti-PRDX2 1:8000 
IgG Anti-rabbit HRP 1:10000 IgG Anti-rabbit HRP 1:3500 
Anti-PRDXSO2/3 1:3000 Anti-PRDXSO2/3 1:2000 
IgG Anti-rabbit HRP 1:5000 IgG Anti-rabbit HRP 1:3500 
3.2.8 Protein Detection 
This step was performed in a dark room, where the membranes were covered 
with a chemiluminescence detection solution from Amersham ECL Western blotting 
detection reagents, GE Healthcare. The membrane is placed in a cassette and then 
covered with detection solution (about 1 ml per membrane) for 2 minutes. Then an x-
ray film (AGFA) was placed on top of the membranes and the cassette was shut in 
order to impress the sheet. It remained closed for a period of time depending on the 
luminous intensity of bands for each protein studied – 15 minutes for PRDX2 and 30 
minutes for PRDXSO2/3. After exposure the x-ray film was revealed in a processor 
(Medical X-Ray Processor - Kodak).  
3.2.9 Determination of Protein Relative Abundance 
After results for each protein (PRDX2 and PRDX SO2/3) identification were 
obtained, the x-ray films (sheets) were scanned and images were saved in JPEG (16 bit) 
format. Subsequently, we analyzed the protein bands, using ImageJ – through 
densitometry. This software allows the selection of an area surrounding the 
protein/band, and the relative amount of protein can be detected by desitometry. 
As mentioned previously, colored membranes (with Ponceau S) were scanned 
and saved as JPEG images. We used these images to quantify the hemoglobin band in 
RBCs and in plasma we quantified the Albumin band, and we used these values to 
normalize PRDX2 and PRDX SO2/3 values. Further details regarding normalization can 
be found in annex V. 
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With the normalized areas obtained by densitometry, graphs were elaborated, 
with different peaks and areas related to the pixel density of each band corresponding 
to each protein in study. 
The data acquired from ImageJ were analyzed using Excel (Microsoft Office 2010 
version). Means and standard deviations were calculated of all samples – Snorers, OSA 
and CPAP, diabetic and non-diabetic. These results were used for graphing and 
statistical analysis. 
3.3 Statistical Analysis  
Descriptive analysis for clinical and analytical data was expressed as mean ± 
standard deviation (SD), and frequency (% values) was used to characterize the groups. 
One-way ANOVA (analysis of variance) was used to statistically compare more than 
two groups; Student-T for independent samples test was used to compare diabetic and 
non-diabetic conditions in the same group set (Snorer or OSA). To evaluate the effect 
of CPAP treatment (before/after) in the OSA group set, Paired Student-T test was used. 
The level of statistical significance was set at 5% (p value < 0.05).  
Correlations of PRDX2 and PRDX SO2/3 (RBCs and Plasma) results with 
polysomnographic and clinical parameters were performed with IBM SPSS Statistics 
24.0 software, using Pearson’s correlation tests. 
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4 Results 
4.1 Peroxiredoxin II in RBCs 
To analyze the different forms PRDX2, reduced, oxidized and hyperoxidized, WB 
method was performed under non-reducing conditions, using an antibody against 
PRDX2 and against the hyperoxidized form, PRDX SO2/3, as shown in figures 4.1 and 
4.6. 
 
Figure 4.1: RBCs results of PRDX2 Western blot detection using the ECL system and 
imaging by X-ray processor. Samples were separated on SDS-PAGE gels before transfer 
to PVDF membranes. Detection of proteins was via the Ab-PRDX2 (dilution 1:20000 – 
methods, see page 29). The samples were grouped into 18 different groups for ease of 
analysis. The order of samples in each group is always the same and is indicated in 
samples 1, 2, 3, 10, 11 and 12 – Control (C), non-treated OSA (OSA) and post CPAP 
treatment (CP) samples, n = 54. Monomeric – 20 kDa – and dimeric – 40 kDa – PRDX2 
forms can be observed.  
Figure 4.1 shows different oligomeric protein forms of PRDX2 having different 
molecular masses that migrated along the gel. These oligomeric forms relate mainly to 
monomeric and dimeric forms (-S-S).  
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The results of the quantification of PRDX2 bands (Figure 4.2) reveal differences 
concerning protein abundance and also concerning its structural forms. In general, we 
can say the monomeric form of this protein is found in less abundance when compared 
with dimeric, oxidized and hyperoxidized forms. It is also possible to say that there is an 
increase in the amount of protein in OSA – CPAP samples compared to the Control group, 
regardless of its structural form. 
 
 
Figure 4.2: RBCs relative protein abundance of PRDX2 monomeric, oxidized and 
hyperoxidized dimeric forms in samples, in Snorers (n=18) and OSA (n=18) groups, and 
after CPAP (n=18) treatment. Significant differences between groups are denoted by 
“*” p < 0.05. 
Regarding the presence of the monomeric PRDX2 form in the RBCs, it is 
noticeable a higher abundance of this form in OSA patients when comparing to the 
control group. After six months of CPAP treatment, this abundance seems to increase 
in non-diabetic OSA patients and decrease in diabetics (Figure 4.3). These differences 
are, however, not significant. Only when analyzing the oxidized dimeric PRDX2 form, 
the increase its abundance after six months of CPAP treatment is statistically 
significant, in non-diabetic OSA patients (Figure 4.4). 
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Figure 4.3: RBCs relative protein abundance of PRDX2 monomeric form in samples, in 
Snorers (n = 18; 16 samples from non-diabetic snorers and 2 samples from diabetic 
snorers) and OSA group (n = 18; 15 samples from non-diabetic OSA patients and 3 
samples from diabetic OSA patients), and after CPAP treatment (n = 18; 15 samples 
from non-diabetic OSA patients and 3 samples from diabetic OSA patients). No 
significant differences were found. 
 
Figure 4.4: RBCs relative protein abundance of PRDX2 oxidized dimeric form in 
samples, in Snorers (n = 18; 16 samples from non-diabetic snorers and 2 samples from 
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diabetic snorers) and OSA group (n = 18; 15 samples from non-diabetic OSA patients 
and 3 samples from diabetic OSA patients), and after CPAP treatment (n = 18; 15 
samples from non-diabetic OSA patients and 3 samples from diabetic OSA patients). 
Significant differences between groups are denoted by “*” p < 0.05. 
 
Figure 4.5: RBCs relative protein abundance of PRDX2 hyperoxidized dimeric form in 
samples, in Snorers (n = 18; 16 samples from non-diabetic snorers and 2 samples from 
diabetic snorers) and OSA group (n = 18; 15 samples from non-diabetic OSA patients 
and 3 samples from diabetic OSA patients), and after CPAP treatment (n = 18; 15 
samples from non-diabetic OSA patients and 3 samples from diabetic OSA patients). 
Significant differences between groups are denoted by “*” p < 0.05, and inner group 
differences are denoted by “+” p < 0.05. 
Concerning the hyperoxidized PRDX2 dimeric form found in the RBCs, it is 
notable a significantly higher abundance of this protein form in diabetic snorer 
patients, comparing to non-diabetics. Hyperoxidized dimeric forms seem to decrease 
in diabetic OSA patients and increase again after six months of CPAP treatment. This 
increase is significant, however, only among non-diabetic OSA patients (Figure 4.5). 
Results for PRDX2 oligomeric forms are grouped and properly marked in Fig. 4.6. 
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Figure 4.6: RBCs relative protein abundance of PRDX2 monomeric, oxidized and 
hyperoxidized dimeric forms for diabetic (Diabetes+) and non-diabetic (Diabetes-) 
patients, in Snorersl (n = 18; 16 samples from non-diabetic snorers and 2 samples from 
diabetic snorers) and OSA groups (n = 18; 15 samples from non-diabetic OSA patients 
and 3 samples from diabetic OSA patients), and after CPAP treatment (n = 18; 15 
samples from non-diabetic OSA patients and 3 samples from diabetic OSA patients). 
Significant differences between groups are denoted by “*” p < 0.05, and inner group 
differences are denoted by “+” p < 0.05. 
To better understand this protein action in patients with OSA and after CPAP 
treatment, we decided to study hyperoxidation in PRDX2 (PRDX SO2/3) through WB 
technique. Results are shown in figure 4.7. 
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Figure 4.7: RBCs results of PRDX SO2/3 Western blot detection using the ECL system and 
imaging by X-ray processor. Samples were separated on SDS-PAGE gels before transfer 
to PVDF membranes. Detection of proteins was via using the Ab-PRDX SO2/3 (dilution 
1:3000 – methods, see page 29). The samples were grouped into 18 different groups 
for ease of analysis. The order of samples in each group is always the same and is 
indicated in samples 1, 2, 3, 10, 11 and 12 – Control (C), non-treated OSA (OSA) and 
post CPAP treatment (CP) samples, n = 54. Monomeric – 20 kDa – dimeric – 40 kDa – 
and multimeric – 220 kDa – forms can be observed. 
In this study, hyperoxidized multimeric forms were detected in some Control 
samples, OSA samples, and also after 6 months of CPAP (Figures 4.7 and 4.8).  
Regarding the quantification obtained from the standardization of the dimeric 
and monomeric hyperoxidized bands (PRDX SO2/3), it is important to note a significant 
increase of the hyperoxidized monomeric form in the OSA group, when compared with 
the control, and also a significant decrease of the dimeric form after CPAP treatment.  
Furthermore, it is possible to observe that, despite being found in lower abundance 
when compared to the remaining protein forms present in the cells, multimeric forms 
are present in major quantity in control and CPAP groups, rather than in OSAs (Figure 
4.8). 
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Figure 4.8: RBCs relative protein abundance of PRDX SO2/3 monomeric, dimeric and 
multimeric hyperoxidized forms in samples, in Snorers (n=18) and OSA (n=18) groups, 
and after CPAP treatment (n=18). Significant differences between groups are denoted 
by “*” p < 0.05. 
 
Figure 4.9: RBCs relative protein abundance of PRDX SO2/3 hyperoxidized monomeric 
form in samples, in Snorers (n = 18; 16 samples from non-diabetic snorers and 2 
samples from diabetic snorers) and OSA group (n = 18; 15 samples from non-diabetic 
OSA patients and 3 samples from diabetic OSA patients). Significant differences 
between groups are denoted by “*” p < 0.05. 
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Looking more closely at the results of the monomeric band PRDX SO2/3 (Figure 
4.9), and comparing diabetic groups with non-diabetic, no differences are seen, except 
for a slight increase in the OSA diabetes group after six months of CPAP treatment, 
however this has no statistical relevance. Only upon analyzing the non-diabetic group, 
is a significant increase of hyperoxidized monomeric form seen in the OSA group 
compared to Control. 
Regarding the hyperoxidized dimeric form PRDX SO2/3 (Figure 4.10), the most 
significant change relies on an accentuated decrease of relative protein abundance of 
this form only in the non-diabetic group, after six months of CPAP treatment.  
 
Figure 4.10: RBCs relative protein abundance of PRDX SO2/3 hyperoxidized dimeric form 
in samples, in Snorers (n = 18; 16 samples from non-diabetic snorers and 2 samples 
from diabetic snorers) and OSA group (n = 18; 15 samples from non-diabetic OSA 
patients and 3 samples from diabetic OSA patients). Significant differences between 
groups are denoted by “*” p < 0.05. 
0,00
0,20
0,40
0,60
0,80
1,00
1,20
Snorers OSA CPAP
R
El
at
iv
e
 P
ro
te
in
 A
b
u
n
d
an
ce
 
PRDX SO2/3 Dimer 
W/o diabetes
Diabetes
* 
 40 
 
 
Figure 4.11: RBCs relative protein abundance of PRDX SO2/3 hyperoxidized multimeric 
form in samples, in Snorers (n = 18; 16 samples from non-diabetic snorers and 2 
samples from diabetic snorers) and OSA group (n = 18; 15 samples from non-diabetic 
OSA patients and 3 samples from diabetic OSA patients).  Significant differences 
between groups are denoted by “*” p < 0.05. 
Finally, in regards to the multimeric hyperoxidized form, it is possible to note 
lower levels in control and OSA groups, and a tendency to increase after six months of 
CPAP treatment in non-diabetic patients. In diabetics, this multimeric form is much 
more abundant in the Control group (however, only one diabetic individual revealed 
de presence of these multimeric structures), it is absent in the OSA group, and shows a 
slight increase after CPAP treatment (Figure 4.11).  
In short, the results for oligomeric forms of PRDX SO2/3 are summarized below, in 
figure 4.12. 
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Figure 4.12: RBCs relative protein abundance of PRDX SO2/3 monomeric, dimeric and 
multimeric hyperoxidized forms for diabetic (Diabetes+) and non-diabetic (Diabetes-) 
patients, in Snorers (n = 18; 16 samples from non-diabetic snorers and 2 samples from 
diabetic snorers) and OSA (n = 18; 15 samples from non-diabetic OSA patients and 3 
samples from diabetic OSA patients) groups, and after CPAP treatment (n = 18; 15 
samples from non-diabetic OSA patients and 3 samples from diabetic OSA patients). 
Significant differences between groups are denoted by “*” p < 0.05. 
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4.2 Peroxiredoxin II in Plasma 
Taking into consideration the previous results obtained from RBCs, we thought it 
pertinent to study the same oligomeric forms of Peroxiredoxin II (PRDX2) in plasma 
samples, with the same cohort used previously. In order to do this, we used the same 
antibodies against PRDX2 and against the hyperoxidized form PRDX SO2/3, as can be 
seen in figures 4.13 and 4.18. Regarding PRDX2, unlike what was seen in RBCs, we 
could only observe two distinct bands: one with a molecular weight of 20 kDa – 
monomer – and another about ≈25 kDa – unknown monomeric form. This same band 
of ≈25 kDa also reacts with PRDX SO2/3 antibody. This hyperoxidation antibody allows 
us to identify besides the ≈25 kDa form, another specific reactive band of about 50 kDa 
(figure 4.18). 
 
Figure 4.13: Plasma results of PRDX2 Western blot detection using the ECL system and 
imaging by X-ray processor. Samples were separated on SDS-PAGE gels before transfer 
to PVDF membranes. Detection of proteins was via using the Ab-PRDX2 (dilution 
1:8000 – methods, see page 29). The samples were grouped into 18 different groups 
for ease of analysis. The order of samples in each group is always the same and is 
indicated in samples 1, 2, 3, 10, 11 and 12 – Control (C), non-treated OSA (OSA) and 
post CPAP treatment (CP) samples, n=54. Two monomeric PRDX2 forms can be 
observed. 
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Regarding the presence of PRDX2 in plasma, in general we can state that there is 
an increase of protein abundance in the OSA group when comparing with the Control 
group, and a decrease after six months of CPAP treatment, this being significant 
(p<0.05) in both the monomeric 20 kDa band and in the ≈25 kDa band (Figure 4.14).  
 
Figure 4.14: Plasma relative protein abundance of PRDX2 20kDa and 25kDa monomeric 
forms in samples, in Snorers (n = 18) and OSA (n = 18) groups, and after CPAP (n = 18) 
treatment. Significant differences between groups are denoted by “*” p<0.05. 
Analyzing the ≈25 kDa form, it is possible to note once more, in both diabetic and 
non-diabetic patients, a slight increase of protein abundance in the OSA group, 
compared to the control, and a decrease after CPAP treatment which is considered 
significant (p < 0.05) in both diabetic and non-diabetic group, as can be seen in the 
graph above (Figure 4.15). However, when looking at the PRDX2 monomeric form (20 
kDa), despite revealing the same tendencies as shown before, i.e. an increase in OSA 
compared with control and a decrease after treatment, in both diabetic and non-
diabetic groups, we can notice a higher abundance of this protein form in diabetic 
controls and non-treated OSA patients, compared to non-diabetics. Nevertheless, after 
six months of CPAP treatment, diabetic patients reveal decrease of protein abundance 
attaining lower levels that those registered among non-diabetics (figure 4.16). Results 
regarding the relative quantification of PRDX2 bands (20 and 25 kDa) in plasma are 
summed up and properly marked in figure 4.17. 
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Figure 4.15: Plasma relative protein abundance of PRDX2 25 kDa monomeric form in 
samples, in Snorers (n = 18; 16 samples from non-diabetic snorers and 2 samples from 
diabetic snorers) and OSA group (n = 18; 15 samples from non-diabetic OSA patients 
and 3 from diabetic OSA patients, and after CPAP treatment (n = 18; 15 samples from 
non-diabetic OSA patients and 3 samples from diabetic OSA patients). Significant 
differences between groups are denoted by “*” p < 0.05, and inner group differences 
are denoted by “+” p < 0.05. 
 
Figure 4.16: Plasma relative protein abundance of PRDX2 20 kDa monomeric form in 
samples, in Snorers (n = 18; 16 samples from non-diabetic snorers and 2 samples from 
diabetic snorers) and OSA group (n = 18; 15 samples from non-diabetic OSA patients 
and 3 from diabetic OSA patients, and after CPAP treatment (n = 18; 15 samples from 
non-diabetic OSA patients and 3 samples from diabetic OSA patients). Significant 
differences between groups are denoted by “*” p < 0.05. 
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Figure 4.17: Plasma relative protein abundance of PRDX2 20kDa and 25 kDa 
monomeric forms for diabetic (Diabetes+) and non-diabetic (Diabetes-) patients, in 
Snorers (n = 18; 16 samples from non-diabetic snorers and 2 samples from diabetic 
snorers) and OSA (n = 18; 15 samples from non-diabetic OSA patients and 3 samples 
from diabetic OSA patients) groups, and after CPAP treatment (n = 18; 15 samples 
from non-diabetic OSA patients and 3 samples from diabetic OSA patients). Significant 
differences between groups are denoted by “*” p < 0.05, and inner group differences 
are denoted by “+” p < 0.05. 
As previously stated, we studied the hyperoxidized forms of PRDX2 (PRDX SO2/3) 
by WB technique, in order to, like in RBCs, try to better understand the function of the 
protein in OSA patients, diabetics and non-diabetics, and after CPAP treatment. Results 
are shown in figure 4.18. 
0,00
0,20
0,40
0,60
0,80
1,00
1,20
Snorers
Diabetes -
Snorers
Diabetes +
OSA
Diabtes -
OSA
Diabetes +
CPAP
Diabetes -
CPAP
Diabetes +
R
e
la
ti
ve
 P
ro
te
in
 A
b
u
n
d
an
ce
 
PRDX 2 
20 kDa
25 kDa
* 
* 
+ 
 46 
 
 
Figure 4.18: Plasma results of PRDX SO2/3 Western blot detection using the ECL system 
and imaging by X-ray processor. Samples were separated on SDS-PAGE gels before 
transfer to PVDF membranes. Detection of proteins was via using the Ab-PRDX SO2/3 
(dilution 1:2000 – methods, see page 29). The samples were grouped into 18 different 
groups for ease of analysis. The order of samples in each group is always the same and 
is indicated in samples 1, 2, 3, 10, 11 and 12 – Control (C), non-treated OSA (OSA) and 
post CPAP treatment (CP) samples, n=54. One monomeric and one higher-order PRDX 
SO2/3 forms can be observed. 
This study revealed two distinct hyperoxidized bands, one with a molecular 
weight of ≈25 kDa (also previously identified with the specific antibody against PRDX2), 
and another of about 50 kDa (Figure 4.18).  
In what concerns the presence of the hyperoxidized PRDX SO2/3 forms in plasma, 
it is important to point out that the ≈25 kDa band’s protein abundance is similar  
among control and OSA groups, but there is, however, a significant decrease after six 
months of CPAP treatment. On the other hand, the results concerning the 50 kDa band 
reveal a significant increase of this hyperoxidized form in OSA group, when compared 
to the control and a significant decrease after treatment (Figure 4.19.) 
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Figure 4.19: Plasma relative protein abundance of PRDX SO2/3 25 kDa and 50 kDa 
hyperoxidized forms in samples, in Snorers (n = 18) and OSA (n = 18) groups, and after 
CPAP (n = 18) treatment. Significant differences between groups are denoted by “*” 
p<0.05. 
 
Figure 4.20: Plasma relative protein abundance of PRDX SO2/3 25 kDa hyperoxidized 
monomeric form in samples, in Snorers (n = 18; 16 samples from non-diabetic snorers 
and 2 samples from diabetic snorers) and OSA group (n = 18; 15 samples from non-
diabetic OSA patients and 3 from diabetic OSA patients, and after CPAP treatment 
(n=18; 15 samples from non-diabetic OSA patients and 3 samples from diabetic OSA 
patients). Significant differences between groups are denoted by “*” p < 0.05. 
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Analyzing more carefully the ≈25 kDa form, no significant alterations have been 
found, unless in the non-diabetic group, where there is a significant decrease of 
protein abundance after CPAP treatment, compared with the OSA group (Figure 4.20). 
Nevertheless, analyzing the hyperoxidized form of 50 kDa, it is possible to verify a 
significant increase of protein abundance in the non-treated OSA group, compared 
with control, and a significant decrease after treatment, in the non-diabetic group 
(Figure 4.21). Diabetic patients show a slight higher abundance of this protein form 
than non-diabetics, maintaining the same tendency described before, i.e. an increase 
in non-treated OSA compared with the control group and a decrease after CPAP 
treatment. These differences are, however, not significant (Figure 4.21).  
Results regarding the relative quantification of PRDX SO2/3 bands (25 and 50 kDa) 
in plasma are summed up and properly marked in figure 4.22. 
 
Figure 4.21: Plasma relative protein abundance of PRDX SO2/3 50 kDa hyperoxidized 
form in samples, in Snorers (n = 18; 16 samples from non-diabetic snorers and 2 
samples from diabetic snorers) and OSA group (n = 18; 15 samples from non-diabetic 
OSA patients and 3 from diabetic OSA patients, and after CPAP treatment (n = 18; 15 
samples from non-diabetic OSA patients and 3 samples from diabetic OSA patients). 
Significant differences between groups are denoted by “*” p < 0.05. 
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Figure 4.22: Plasma relative protein abundance of PRDX SO2/3 25kDa and 50 kDa 
hyperoxidized forms for diabetic (Diabetes+) and non-diabetic (Diabetes-) patients, in 
Snorers (n = 18; 16 samples from non-diabetic snorers and 2 samples from diabetic 
snorers) and OSA (n = 18; 15 samples from non-diabetic OSA patients and 3 samples 
from diabetic OSA patients) groups, and after CPAP treatment (n = 18; 15 samples 
from non-diabetic OSA patients and 3 samples from diabetic OSA patients). Significant 
differences between groups are denoted by “*” p < 0.05. 
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4.3 RBCs results for PRDX2 and PRDX SO2/3 
Correlation with PSG and Clinical Parameters                   
Correlations between RBC PRDX2 redox oligomeric status and 
polysomnographic/clinical parameters for OSA patients are shown in table 4.1. 
Monomeric and dimeric forms positively correlate to PSG parameters and negatively 
correlate to CBC results, while multimeric forms positively correlate with Hb A1C. 
 
Table 4.1: Correlations between RBC PRDX2 and PSG/Clinical parameters concerning 
non-treated patients 
PRDX2 
Snorers + OSA (N=36) 
Correlation Pearson r Value p Value 
Monomer 
EPW  -,334(*) 0,046 
RDI ,368(*) 0,027 
T90 ,386(*) 0,020 
Min sat (%) -,366(*) 0,028 
ODI ,421(*) 0,010 
Hemoglobin  -,376(*) 0,024 
Hematocrit  -,395(*) 0,017 
WBC count x 10^9/L  -,411(*) 0,013 
S-S Dimer no significant correlation observed 
S-S/S-S Dimer 
Triglycerides ,406(*) 0,014 
RDW  -,367(*) 0,028 
SO2/3 Monomer 
EPW -.334(*) 0,046 
RDI .368(*) 0,027 
T90 .386(*) 0,020 
Min sat (%) -.366(*) 0,028 
ODI .421(*) 0,010 
Hemoglobin  -,376(*) 0,024 
Hematocrit  -,395(*) 0,017 
WBC count x 10^9/L  -,411(*) 0,013 
S-S/SO2/3 Dimer 
Triglycerides  .458(**) 0,005 
Platelets, count x 10^9/L  .399(*) 0,016 
SO2/3 Multimer Hb A1C  .783(*) 0,037 
**. Correlation is significant at the 0.01 level (2-tailed). 
  *. Correlation is significant at the 0.05 level (2-tailed). 
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Table 4.2: Correlations between RBC PRDX2 and PSG/Clinical parameters after CPAP 
treatment 
PRDX2 
CPAP ALL (N=18) 
Correlation Pearson r Value p Value 
Monomer no significant correlation observed 
S-S Dimer WBC count x 10^9/L  ,585(*) 0.011 
S-S/S-S Dimer Triglycerides  ,585(*) 0.011 
SO2/3 Monomer no significant correlation observed 
S-S/SO2/3 Dimer MCHC  ,660(**) 0.003 
SO2/3 Multimer no significant correlation observed 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
After CPAP treatment, different correlations are shown – table 4.2. Dimeric 
forms positively correlate with CBC results, and no correlations were observed neither 
in monomeric nor multimeric forms. Remaining detailed tables concerning correlation 
concerning specific groups are shown in supplemental data (annex IV). 
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4.4 Plasma results for PRDX2 and PRDX SO2/3 
Correlation with PSG and Clinical Parameters  
Correlations between Plasma PRDX2 redox oligomeric status and 
polysomnographic/clinical parameters for OSA patients are shown in table 4.3. PRDX 2 
monomeric forms positively correlate mainly with glucose metabolism related 
parameters, as well as hyperoxidized forms. Also, PDRX2 monomeric form revealed a 
positive correlation with Hb and a negative correlation with homocysteine. 
 
Table 4.3: Correlations between plasma PRDX2 and PSG/Clinical parameters 
concerning non-treated patients 
PRDX2 
Snorers + OSA ALL (N=36) 
Correlation Pearson r Value p Value 
PRDX2 25 kDa Oximetry ,402(*) 0,017 
PRDX2 20 kDa 
Monomer 
Fasting glucose ,491(**) 0,002 
Hb A1C ,441(**) 0,007 
HOMA-IR ,457(**) 0,005 
Homocysteine -,427(**) 0,009 
Hemoglobin ,332(*) 0,048 
SO2/3 25 kDa Oximetry ,376(*) 0,026 
SO2/3 50 kDa 
Cervical perimeter ,346(*) 0,048 
Min sat (%) -,338(*) 0,044 
Fasting glucose ,342(*) 0,042 
Hb A1C ,339(*) 0,043 
**. Correlation is significant at the 0.01 level (2-tailed).     
*. Correlation is significant at the 0.05 level (2-tailed).     
 
Table 4.4: Correlations between plasma PRDX2 and PSG/Clinical parameters 
concerning non-treated patients 
PRDX2 
CPAP ALL (N=18) 
Correlation Pearson r Value p Value 
PRDX2 25 kDa 
Days w/o use -,600(**) 0,008 
MCHC  -,495(*) 0,037 
PRDX2 20 kDa 
Monomer 
Hematocrit  -,477(*) 0,046 
RDW  ,587(*) 0,010 
SO2/3 25 kDa no significant correlation observed 
SO2/3 50 kDa no significant correlation observed 
**. Correlation is significant at the 0.01 level (2-tailed). 
  *. Correlation is significant at the 0.05 level (2-tailed). 
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After CPAP treatment, different correlations are shown – table 4.4. Despite no 
major correlation was observed, plasma PRDX2 monomeric forms reveled a negative 
correlation with some CBC results. No glucose metabolism related correlations were 
observed after six months of CPAP therapy, in none of the oligomeric plasma PRDX2 
forms. Remaining detailed tables concerning PRDX2 correlation with PSG/Clinical 
parameters of specific groups are shown in supplemental data (annex VI). 
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5 Discussion 
Previous studies developed by INSA Proteomics Laboratory have showed that 
monomeric and dimeric forms of a RBC antioxidant enzyme, PRDX2, were significantly 
hyperoxidized in OSA RBCs, mainly during the morning, suggesting severe oxidative 
stress and altered antioxidant homeostasis in OSA RBC. Six months of CPAP treatment 
decreased this hyperoxidation and generated multimeric hyperoxidized forms 
associated with chaperone function of PRDX2, described to enhance cell stress-
resistance 46. Levels of oxidized PRDX2 correlated to PSG and metabolic parameters in 
these patients. Therefore, the redox/oligomeric state of RBC PRDX2 has been 
proposed by these authors as a promising candidate biomarker for OSA severity and 
treatment monitoring 39.   
In this work, we intended to go further with this investigation by studying in a 
larger cohort of patients the impact of comorbidities, namely diabetes, on the morning 
redox/oligomeric state of RBC PRDX2 before and after CPAP therapy. Overall, the 
results corroborated the previous data by showing a significant increase in the morning 
level of hyperoxidized monomeric/dimeric PRDX2 forms in OSA patients with/without 
diabetes compared with snorer ones. The hyperoxidized multimeric form – associated 
with chaperone protective function of PRDX2 – was observed in some subjects, mainly 
in snorer patients (six of 18, one was diabetic) compared with OSA patients (one of 18, 
none were diabetics).  
No significant differences were observed between diabetic and non-diabetic OSA 
patients in regards to the level of hyperoxidation in the monomeric and dimeric forms 
of PRDX2, although dimeric forms showed a tendency, still not significant, to be less 
hyperoxidized in diabetic OSA patients when compared with OSA non-diabetic ones. 
Interestingly, as mentioned above, none of the OSA diabetic patients showed the 
presence of hyperoxidized PRDX2 multimers. These data suggest that the putative 
stress-resistance effect conferred by these hyperoxidized PRDX2 multimers seemed to 
be severely compromised in OSA patients with diabetes comorbidity. 
Six months of CPAP therapy decreased the hyperoxidation level of monomeric 
and dimeric forms of OSA RBC PRDX2, as previously shown 39. However, this effect was 
significantly evident in dimeric PRDX2 forms in non-diabetic patients when compared 
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with diabetic ones.  In diabetic OSA patients, hyperoxidation seemed to remain higher 
in PRDX2 monomers and dimers after treatment. 
However, CPAP treatment showed to increase the level of PRDX2 multimeric 
protective structures in OSA patients, with higher evidence in OSA patients without 
diabetes, in response to treatment.  Further studies will be necessary to better 
elucidate the therapeutic effect of CPAP-induced hyperoxidized PRDX2 multimers in 
OSA patients and its higher modulation under diabetes comorbidity.  
In general, the correlation study between redox oligoforms of PRDX2 and 
patients clinical parameters showed mainly that the morning level of hyperoxidized 
monomeric forms of PRDX2 positively correlated to PSG parameters such as RDI, ODI, 
T90%, while the level of S-S/SO2/3 dimer and SO2/3 multimers showed a positive 
correlation with metabolic parameters, triglycerides and HbA1C, respectively.  
A previous study by the laboratory performed with a smaller cohort of patients 
(n=20), which included mild OSA patients, also showed a positive correlation between 
the morning level of hyperoxidized PRDX2 monomers and PSG parameters, but only 
with PSG-arousal index, while the morning level of S-S/SO2/3 dimer (but not multimers) 
showed a larger positive correlation with metabolic parameters such as HbA1C, insulin 
and HOMA-IR 39. These data prompt the authors to suggest that during the morning, 
the non-peroxidase (hyperoxidation) cycle of PRDX2 predominates in OSA and is 
mainly associated with the metabolic status of the patients.       
Here the study was performed with a larger cohort of subjects (n=36), and 
included only moderate/severe OSA patients with/without diabetes, which may 
explain some observed differences between this study and the previous one. Although 
herein the data confirmed that morning increased the predomination of 
hyperoxidation PRDX2 cycle in OSA, it also seemed to be associated, not only with the 
metabolic status, but also with the OSA severity PSG parameters. Interestingly, 
however, is that the level of protective hyperoxidized multimers, which was mainly 
observed in Snorer patients, strongly positively correlated with several glycemic 
parameters in this group of patients. In patients with moderate/severe OSA 
with/without diabetics there was no such correlation. This data suggested that in the 
presence of moderate/severe OSA-induced hypoxia/sleep disruptions, patients may 
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have a lower capacity to produce PRDX2 multimeric protective forms in response to 
increased plasma glucose and/or RBC Hb1AC.   
The correlation study, which studied OSA patients before and after CPAP, 
showed that before treatment, the level of PRDX2 dimers (oxidized/hyperoxidized) 
positively correlated with PSG-minimum oxygen saturation parameter, which is known 
to associated with OSA severity 47.  After treatment, this correlation was not observed, 
i.e., had ceased to exist.  Other (positive/negative) correlations between clinical 
parameters and the different redox/oligomeric states of PRDX2 before and after CPAP, 
were obtained (see annex IV), the interpretation of which needs further investigation.  
After studying the PRDX2 in RBCs, we decided it would be interesting to recreate 
the same experience, but this time testing plasma samples, in order to understand the 
state of PRDX2 oligomeric redox-status in plasma. We used the same cohort, in order 
to further compare and possibly relate plasma to RBC results. 
Upon analyzing plasma proteins separated by reduced SDS-PAGE, we detected 
two immune-reactive bands (20 kDa and 25 kDa) using the Ab-PRDX2 and two 
immune-reactive bands (25 KDa a 50 kDa) using the Ab-PRDXSO2/3 that is specific for 
hyperoxidized forms of PRDX1-4. From this data, we assumed 20 kDa and 25kDa bands 
to be PRDX2 forms, namely non-oxidized and hyperoxidized forms, respectively. Since 
the 50 kDa band did not react with the Ab-PRDX2, we considered this reactive band 
may correspond to PRDXs 1 or 4, excluding PRDX2 or PRDX3 (the latter is mostly found 
in mitochondria) 44.  
Overall, the results showed that the OSA patients with/without diabetes had 
higher blood circulating levels of PRDX2, especially hyperoxidized forms, and 
hyperoxidized PRDXs 1/4.  Six months of CPAP treatment reduced significantly the 
plasma levels of hyperoxidized PRDXs but only in OSA patients without diabetes. In 
OSA patients with diabetes only circulating levels of non-oxidized PRDX2 were reduced 
after treatment.  
This study also brought interesting results concerning correlations between 
PRDXs redox state in plasma and PSG/clinical parameters. The plasma level of non-
oxidized PRDX2 and hyperoxidized PRDXs 1/4 positively correlated with several 
glucose-metabolism parameters, such as fasting glucose, Hb A1C and/or HOMA-IR. A 
positive correlation between non-oxidized PRDX2 and glycemic parameters was also 
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observed when the OSA diabetic group is separately analyzed.  After CPAP, those 
correlations were no longer observed. However, in the diabetic OSA group, a positive 
correlation was observed between non-oxidized forms of PRDX2 and metabolic 
parameters, namely insulin and Hb A1C, possibly meaning that the glycemic status of 
these patients unchanged after treatment.   
These results confirm previous studies reporting higher levels of plasma PRDXs 
(PRDX1,2,4 and 6) in the diabetic patients than in the healthy ones 48,49. However, 
differential associations of circulating PRDXs levels with indicators of cardiovascular 
risk factors in type 2 diabetes mellitus were observed 48,49. For example, PRDX2 and 
PRDX6 were found to be negatively correlated with fasting blood glucose and Hb A1C. 
In contrast, PRDX1 levels were positively correlated with low-density lipoprotein and C-
reactive protein levels, and PRDX4 levels were negatively correlated with triglycerides. 
Differences in the type of cohort studied and the quantification method used in the 
analysis may explain some of the contradictions this study showed concerning the 
positive correlation between PRDXs and glycemic profile that these authors found. This 
result should encourage further research in order to better clarify the impact of these 
PRDXs in diabetic patients with/without OSA syndrome and the benefic effect of CPAP 
treatment in glycemic control in these patients. 
Intracellular PRDX2 is a peroxidase and chaperone protein 43, whereas 
extracellular PDRX2 , which is stress-induced and secreted from different cells such as 
activated macrophages, presents chemokine-like activity, enabling induction of 
inflammatory responses 50. Herein, no correlation was found between the level of the 
different redox/oligomeric states of RBC PRDX2 and those PRDXs from plasma, PRDX2 
(non-oxidized/oxidized) or PRX1/4 SO2/3.   More studies will be needed to better define 
the role(s) of different PRDXs proteoforms in different cells and subcellular location in 
diseases associated with redox imbalance oxidative conditions such as OSA and OSA-
associated metabolic disorders.    
There are some limitations of this study, such as reduced sample size and female 
gender exclusion. Also, the control group was constituted by non-completely healthy 
snorer subjects, the snorer diabetics group was constituted by only two individuals and 
the non-diabetic OSA group included patients with higher levels of blood insulin and 
HOMA-IR. Taken all together, this is limiting for data generalization. Although patients 
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were instructed to follow a restricted diet for three days before urine/blood collection 
to minimize the impact on antioxidant status, their dietary habits were not fully 
controlled. Validation analyses were performed on -80 ºC stored samples, which could 
introduce some bias in the molecular events of both control and disease samples.  
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6 Conclusion 
In summary, the present findings confirmed previous laboratory data, showing 
that the antioxidant defense and/or redox-signaling involving RBC PRDX2 seemed 
highly modulated and correlated with OSA severity and/or metabolic status of the 
patients. Six months of CPAP significantly increased the chaperone/transduction 
signaling function of RBC PRDX2 that might be linked with beneficial effects of CPAP in 
improving oxidative-stress and the metabolic status of the patients.  
However, diabetes comorbidity in these patients appears to compromise these 
modulations in PRDX2 redox/oligomeric status. Overall, diabetes seems to worsen 
OSA’s implications, as the presence of oxidative stress caused by hypoxia, along with 
glucose metabolism-induced problems, seems to restrain the formation of higher 
order oligomers in RBCs. Nevertheless, we noted a decrease of plasma PRDXs stress-
induced inflammation pathways after CPAP treatment. Also, interesting correlations 
were noted between plasma PRDX2 and PSG/clinical parameters, especially those 
related to glucose-metabolism parameters, thus deserving special attention in further 
studies. 
PRDX2’s oligomeric redox-state relation to hemoglobin autoxidation and PRDX’s 
excretion from blood cells to plasma are critical points which must be carefully 
analyzed in order to further validate PRDX2’s promising potential as a biomarker 
candidate for OSA severity and metabolic status. 
Future studies encompass different proteomic approaches.  
2D-DIGE individual studies are currently in progress. Further LC-MS/MS studies 
might be needed in order to further investigate PTM involved in PRDX2 redox and 
signaling pathways. 
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8 Annexes 
Annex I 
Solutions Composition 
Incomplete Transfer Buffer (10xs) 
30,2g Tris-HCL 0,025 M 
144g Glycine 0,192 M 
Add type II water for a final volume of 1L 
 
Complete Transfer Buffer  
100 mL Incomplete Transfer Buffer 
200 mL Methanol 
Add ultrapure water for a final volume of 1L 
 
Ponceau Solution at 0,1% in 5% de Acetic Acid 
50 mL Ponceau S at 0,1% 
450 mL acetic acid at 5% 
 
PBS 1x (Saline Phosphate Buffer) 
100 mL mineral medium 10xs 
900 mL ultrapure water 
 
PBS-T (Saline Phosphate Buffer w/ Tween 20 at 0,1%) 
100 mL PBS 1x 
900 mL ultrapure water 
1 mL Tween 20 at 0,1% 
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Annex II 
Total protein quantification for RBCs samples (1:200) of Snorer, OSA and OSA – CPAP 
individuals (N=54) 
 
 
 
 
 
 
 
 
 
Table Annex II. 1: Absorbance 
values for standards. 
Standards 
Absorbance 
(λ= 660 nm) 
Mean 
0 0,072 0,072 0,072 
125 0,098 0,094 0,096 
250 0,144 0,153 0,1485 
500 0,248 0,251 0,2495 
750 0,351 0,343 0,347 
1000 0,463 0,46 0,4615 
1500 0,61 0,679 0,6445 
2000 0,809 0,818 0,8135 
Samples 
1:200 
Volume for 
70 μG  
protein (μL) 
Samples 
1:200 
Volume for 
70 μG 
protein (μL) 
Samples 
1:200 
Volume for 
70 μG 
protein (μL) 
C1 47,6 OSA1 42,0 CP1 50,0 
C2 42,7 OSA2 46,0 CP2 49,3 
C3 84,7 OSA3 42,2 CP3 47,4 
C4 50,7 OSA4 46,4 CP4 47,8 
C5 50,0 OSA5 42,7 CP5 48,6 
C6 50,8 OSA6 42,3 CP6 53,2 
C7 47,8 OSA7 48,3 CP7 50,8 
C8 48,5 OSA8 46,4 CP8 48,9 
C9 52,8 OSA9 51,6 CP9 45,8 
C10 51,4 OSA10 45,6 CP10 47,1 
C11 43,9 OSA11 42,0 CP11 46,5 
C12 52,5 OSA12 47,0 CP12 32,6 
C13 54,0 OSA13 46,4 CP13 40,6 
C14 49,3 OSA14 41,9 CP14 48,3 
C15 53,8 OSA15 46,9 CP15 51,5 
C16 51,1 OSA16 44,6 CP16 46,3 
C17 43,8 OSA17 45,1 CP17 48,5 
C18 52,6 OSA18 49,1 CP18 46,2 
Table Annex II. 2: Volume needed to adjust each RBC sample to 70 μG of total protein 
Figure Annex II. 1: Calibration line used to calculate the 
volume of RBC sample needed to adjust to 70 μG 
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Total protein quantification on Plasma samples (1:10) of Snorer, OSA and OSA – 
CPAP individuals (N=54) 
 
  
Table Annex II. 3: Absorbance 
values for standards. 
Standards 
Absorbance 
(λ= 660 nm) 
Mean 
0 0,067 0,072 0,070 
125 0,093 0,088 0,091 
250 0,145 0,138 0,142 
500 0,243 0,229 0,236 
750 0,353 0,330 0,342 
1000 0,432 0,391 0,412 
1500 0,616 0,558 0,587 
2000 0,748 0,720 0,734 
Samples 
1:10 
Volume 
for 40 μG 
protein 
(μL) 
Volume of 
Ultra-pure 
Water  
Samples 
1:10 
Volume 
for 40 μG 
protein 
(μL) 
Volume of 
Ultra-pure 
Water 
Samples 
1:10 
Volume 
for 40 μG 
protein 
(μL) 
Volume of 
Ultra-pure 
Water 
C1 5,4 1,1 OSA1 4,7 1,8 CP1 4,8 1,7 
C2 5,5 1,0 OSA2 5,0 1,5 CP2 5,4 1,1 
C3 5,3 1,2 OSA3 4,7 1,8 CP3 5,0 1,5 
C4 5,3 1,2 OSA4 5,4 1,1 CP4 5,1 1,4 
C5 5,1 1,4 OSA5 5,1 1,4 CP5 5,1 1,4 
C6 4,8 1,7 OSA6 5,1 1,4 CP6 5,1 1,4 
C7 5,2 1,3 OSA7 5,2 1,3 CP7 5,2 1,3 
C8 4,8 1,7 OSA8 5,0 1,5 CP8 5,2 1,3 
C9 4,7 1,8 OSA9 4,7 1,8 CP9 4,9 1,6 
C10 4,8 1,7 OSA10 4,8 1,7 CP10 4,6 1,9 
C11 5,0 1,5 OSA11 4,4 2,1 CP11 4,7 1,8 
C12 4,5 2,0 OSA12 4,9 1,6 CP12 4,9 1,6 
C13 5,2 1,3 OSA13 4,9 1,6 CP13 4,7 1,8 
C14 5,5 1,0 OSA14 5,0 1,5 CP14 5,3 1,2 
C15 5,1 1,4 OSA15 5,4 1,1 CP15 5,4 1,1 
C16 4,7 1,8 OSA16 5,5 1,0 CP16 5,2 1,3 
C17 5,5 1,0 OSA17 4,9 1,6 CP17 5,0 1,5 
C18 4,9 1,6 OSA18 5,2 1,3 CP18 5,0 1,5 
Table Annex II. 4: Volumes needed to adjust each Plasma sample to 40 μG of total protein 
Figure Annex II. 2: Calibration line used to calculate the 
volume of Plasma sample needed to adjust to 40 μG 
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Annex III 
Table Annex III. 1: Demographic, Polysomnographic and Analytical Characterization 
Demographic, Polysomnographic and Analytical Characterization  
Demographic and PSG 
parameters 
Screened Subjects 
Mean (St Dev) p value 
Snorers    
(n=18)  
OSA       
  (n=18) 
CPAP     
(n=18) 
ALL OSA CPAP W/o diabetes Diabetes 
Snorers  
vs. OSA 
OSA vs. 
CPAP 
Diabetes vs. 
W/o diabetes 
Diabetes vs. 
W/o diabetes 
Snorers  
vs. OSA 
OSA vs. 
CPAP 
Snorers  
vs. OSA 
OSA vs. 
CPAP 
Age (years) 45,8 47,4  -  NS  n/a   NS   -   NS   n/a  0,028  n/a  
Habits                       
Current Smoking (n) 5 3  -   -   -   -   -   -   -   -   -  
Current Drinking (n) 10 14  -   -   -   -   -   -   -   -   -  
EPW Score  10,4 (5,4)   8,8 (3,6)   5,8 (4,2)   NS  0,026 0,024  NS   NS  NS NS  NS 
Observational features                       
Morning arterial pressure (mmHg) * 
135,5 (21,0)/ 
83,3 (12,3) 
 142,2 (22,8)/ 
90,2 (14,7)  
 -   NS   n/a   NS   -   NS   n/a  NS  n/a  
BMI (kg/m2)  28,1 (3,4)   31,3 (3,3)   -      0,0014     n/a  NS  -  0,008  n/a  NS  n/a  
Abdominal perimeter (cm)  100,1 (8,4)   109,7 (10,0)   -      0,0009     n/a  NS  -  0,004  n/a  NS  n/a  
Comorbidities                       
Hypertension (n) 9 13  -   -   -   -   -   -   -   -   -  
Respiratory diseases (n) 0 3  -   -   -   -   -   -   -   -   -  
Dyslipidemia (n) 10 14  -   -   -   -   -   -   -   -   -  
Diabetes (n) 2 6  -   -   -   -   -   -   -   -   -  
Polysomnographic parameteres                       
RDI (events/h)  2,8 (1,2)   50,2 (21,6)   -  7,01E-11  n/a   NS   -  2,12E-10  n/a  NS  n/a  
Arousal Index (events/h)  13,8 (6,3)   31,5 (17,3)   -      0,0003     n/a   NS   -  2,05E-04  n/a  0,023  n/a  
Minimum arterial saturation (%)  88,1 (4,3)   76,1 (6,6)   -  2,41E-07  n/a   NS   -  1,61E-07  n/a  NS  n/a  
ODI (events/h)  2,7 (3,5)   42,2 (22,4)   -  1,45E-08  n/a   NS   -  4,38E-07  n/a  0,011  n/a  
T90 (%)  0,1 (0,1)   12,7 (14,6)   -      0,0008     n/a   NS   -  0,004  n/a  NS  n/a  
Sleep efficiency (%)  79,7 (11,7)   77,1 (13,6)   -   NS   n/a   NS   -   NS   n/a  NS  n/a  
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CPAP Record              
Number of days without use  −   −   55,2 (69,3)   -   n/a   -   NS   -   n/a   -   n/a  
Total of recording days  −   −   192,3 (32,3)   -   n/a   -   NS   -   n/a   -   n/a  
Use per night (minutes)  −   −   266,7 (146,0)   -   n/a   -   NS   -   n/a   -   n/a  
Residual AHI (events/hour)  −   −   2,0 (1,4)   -   n/a   -   NS   -   n/a   -   n/a  
Analytical parameteres                       
Glycemic profile                         
Glucose (70-110 mg/dl)  101,9 (27,2)   115,4 (35,3)   106,4 (26,5)   NS   NS  5,98E-06 0,002  NS   NS   NS   NS  
Hb A1C (4-6%)  5,8 (0,8)   6,4 (1,1)   6,3 (1,2)   NS   NS  5,05E-06 0,003 0,037  NS   NS   NS  
Insulin (3-25 mU/L)  14,7 (7,5)   21,4 (11,0)   31,6 (33,9)  0,0401  NS  NS   NS  0,023  NS   NS   NS  
HOMA-IR (≥ 3,8)  3,9 (3,4)   6,1 (3,0)   8,5 (8,9)  0,0522  NS  NS  NS  0,008  NS   NS   NS  
Lipid profile                       
Cholesterol (< 190 mg/dl)  189,3 (39,6)   187,4 (30,7)   180,1 (32,9)   NS   NS   NS   NS   NS  NS   NS   NS  
Triglycerides (< 150 mg/dl)  131,6 (77,6)   142,8 (82,4)   143,7 (100,8)   NS   NS   NS   NS   NS   NS   NS   NS  
Cardiovascular marker                       
Homocysteine (3,7-13,9 µmol/L)  14,3 (3,1)   15,5 (2,8)   16,4 (2,8)   NS   NS   NS   NS   NS   NS   NS   NS  
Urinary catecholamines                       
Adrenalin (1,7-22,4 µg/24h)  22,8 (18,6)   17,4 (12,2)   21,3 (15,1)   NS   NS   NS   NS   NS   NS   NS   NS  
Nor-adrenalin (12,1-85,5 µg/24h)  60,4 (25,6)   81,9 (45,8)   58,8 (28,4)   NS   NS   NS   NS   NS   NS   NS   NS  
Complete Hemogram                       
RBC (4.5-5.9x10^12/L)  5,2 (0,3)   5,1 (0,4)   5,1 (0,3)   NS   NS  0,046   NS   NS   NS   NS   NS  
Hemoglobin (13-17.5 g/dl)  15,5 (0,7)   15,7 (1,4)   15,1 (1,2)   NS   NS   NS   NS   NS   NS   NS   NS  
Hematocrit (40-50%)  45,7 (2,3)   46,3 (4,1)   45,1 (3,2)   NS   NS   NS   NS   NS   NS   NS   NS  
MCV (80-97 fl)  88,8 (4,6)   89,9 (4,5)   89,4 (4,6)   NS   NS   NS   NS   NS   NS   NS   NS  
MCH (27-33 pg)  30,2 (1,5)   30,4 (1,6)   30,0 (1,7)   NS   NS  0,036  NS   NS   NS   NS   NS  
MCHC (31.5-35.5 g/dl)  34,0 (1,0)   33,9 (1,0)   33,6 (0,7)   NS   NS   NS   NS   NS   NS   NS   NS  
RDW (11.5-14.5)  13,8 (0,5)   13,7 (0,7)   13,7 (0,8)   NS   NS   NS   NS   NS   NS   NS   NS  
Leukocytes (4.0-11x10^9/L)  7,5 (2,2)   6,9 (1,9)7   6,3 (1,3)   NS   NS   NS   NS   NS   NS   NS   NS  
Platelets (150-450 10
3
µL)  229,2 (41,3)   217,1 (49,0)   196,7 (47,2)   NS   NS   NS   NS   NS   NS   NS   NS  
NS: non-statistical meaning ; n/a: not-applicable 
         * PA max / PA min 
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Annex IV 
RBCs results for PRDX2 and PRDX SO2/3 Correlation with PSG and 
Clinical Parameters  
Table Annex IV. 1: RBC PRDX2 correlations with PSG/Clinical parameters for snorer 
group 
PRDX2 
Snorers ALL (N=18) 
Correlation Pearson r Value p Value 
Monomer EPW  -,497(*) 0,036 
S-S Dimer no significant correlation observed 
S-S/S-S Dimer no significant correlation observed 
SO2/3 Monomer 
EPW  -.505(*) 0,032 
Noradrenalin U24 -.474(*) 0,047 
S-S/SO2/3 Dimer no significant correlation observed 
SO2/3 Multimer 
T90 ,483(*) 0,042 
Fasting glucose  ,776(**) 0,000 
Hb A1C  ,642(**) 0,004 
HOMA-IR ,737(**) 0,000 
Noradrenalin U24 ,565(*) 0,015 
**. Correlation is significant at the 0.01 level (2-tailed).     
*. Correlation is significant at the 0.05 level (2-tailed).     
  
Table Annex IV. 2: RBC PRDX2 correlation with PSG/Clinical parameters for snorer 
group without diabetes 
PRDX2 
Snorers W/o diabetes (N=16) 
Correlation Pearson r Value p Value 
Monomer Sat min (%) ,516(*) 0,041 
S-S Dimer Oximetry ,631(*) 0,012 
S-S/S-S Dimer Fasting glucose  ,526(*) 0,037 
SO2/3 Monomer 
Insulin  ,560(*) 0,024 
HOMA-IR  ,559(*) 0,024 
S-S/SO2/3 Dimer 
Fasting glucose  ,691(**) 0,003 
Cholesterol  ,672(**) 0,004 
SO2/3 Multimer 
Height -,963(*) 0,037 
Cholesterol  ,950(*) 0,050 
**. Correlation is significant at the 0.01 level (2-tailed). 
  *. Correlation is significant at the 0.05 level (2-tailed). 
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Table Annex IV. 3: RBC PRDX2 correlations with PSG/Clinical parameters for OSA group 
PRDX2 
OSA ALL (N=18) 
Correlation Pearson r Value p Value 
Monomer no significant correlation observed 
S-S Dimer Min sat (%) ,477(*) 0,045 
S-S/S-S Dimer 
Min sat (%) ,615(**) 0,007 
MCHC   ,489(*) 0,039 
SO2/3 Monomer 
RBC count  -.624(**) 0,006 
Hemoglobin  -.613(**) 0,007 
Hematocrit  -.624(**) 0,006 
WBC count x 10^9/L  -.484(*) 0,042 
S-S/SO2/3 Dimer 
Age -,502(*) 0,034 
Systolic BP -,500(*) 0,035 
Triglycerides  ,469(*) 0,050 
Platelets, count x 10^9/L  ,521(*) 0,026 
SO2/3 Multimer MCHC  ,473(*) 0,047 
**. Correlation is significant at the 0.01 level (2-tailed). 
  *. Correlation is significant at the 0.05 level (2-tailed). 
   
Table Annex IV. 4: RBC PRDX2 correlations with PSG/Clinical parameters for non-
treated OSA group without diabetes 
PRDX2 
OSA W/o diabetes (N=15) 
Correlation Pearson r Value p Value 
Monomer 
Triglycerides -,515(*) 0,050 
Homocysteine ,518(*) 0,048 
   S-S Dimer Min sat (%) ,532(*) 0,041 
S-S/S-S Dimer Min sat (%) ,624(*) 0,013 
SO2/3 Monomer 
RBC count  -,669(**) 0,006 
Hemoglobin  -,654(**) 0,008 
WBC count x 10^9/L -,540(*) 0,038 
Hematocrit  -,682(**) 0,005 
S-S/SO2/3 Dimer 
Age -,573(*) 0,026 
Diastolic BP -,642(**) 0,010 
Homocysteine -,585(*) 0,022 
RDW -,576(*) 0,025 
SO2/3 Multimer Systolic BP ,565(*) 0,028 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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Table Annex IV. 5: RBC PRDX2 correlations with PSG/Clinical parameters for diabetic 
non-treated OSA group 
 
PRDX2 
OSA diabetes (N=3) 
Correlation Pearson r Value p Value 
Monomer MCV ,999(*) 0,025 
S-S Dimer 
MCHC ,999(*) 0,034 
Weight ,998(*) 0,039 
Abdominal perimeter ,998(*) 0,042 
S-S/S-S Dimer Adrenalin 1,000(*) 0,016 
SO2/3 Monomer no significant correlation observed 
S-S/SO2/3 Dimer 
Weight ,998(*) 0,040 
Abdominal perimeter ,998(*) 0,037 
MCHC ,997(*) 0,045 
SO2/3 Multimer .(a) 
**. Correlation is significant at the 0.01 level (2-tailed).     
*. Correlation is significant at the 0.05 level (2-tailed).     
a. Cannot be computed because at least one of the variables is constant. 
  
Table Annex IV. 6: RBC PRDX2 correlations with PSG/Clinical parameters for non-
diabetic OSA patients after CPAP treatment 
PRDX2 
CPAP W/o diabetes (N=15) 
Correlation Pearson r Value p Value 
Monomer no significant correlation observed 
S-S Dimer 
Hb A1C ,545(*) 0,036 
Adrenalin ,558(*) 0,031 
WBC count x 10^9/L ,623(*) 0,013 
S-S/S-S Dimer 
Triglycerides ,596(*) 0,019 
MCHC ,518(*) 0,048 
SO2/3 Monomer no significant correlation observed 
S-S/SO2/3 Dimer MCHC  ,705(**) 0,003 
SO2/3 Multimer Hb A1C ,559(*) 0,030 
**. Correlation is significant at the 0.01 level (2-tailed). 
  *. Correlation is significant at the 0.05 level (2-tailed). 
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Table Annex IV. 7: RBC PRDX2 correlations with PSG/Clinical parameters for diabetic 
OSA patients after CPAP treatment 
PRDX2 
CPAP diabetes (N=3) 
Correlation Pearson r Value p Value 
Monomer Days w/o use -,998(*)  0,042 
S-S Dimer 
Hb A1C 1,000(*)  0,012 
Hemoglobin ,998(*)  0,042 
S-S/S-S Dimer no significant correlation observed 
SO2/3 Monomer Insulin 1,000(*)  0,008 
S-S/SO2/3 Dimer 
P95 -,998(*) 0,039 
MCH -1,000(**) 0,010 
SO2/3 Multimer no significant correlation observed 
**. Correlation is significant at the 0.01 level (2-tailed). 
  *. Correlation is significant at the 0.05 level (2-tailed). 
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Plasma results for PRDX2 and PRDX SO2/3 Correlation with PSG 
and Clinical Parameters 
Table Annex IV. 8: Plasma PRDX2 correlations with PSG/Clinical parameters for snorer 
group 
PRDX2 
Snorers ALL (N=18) 
Correlation Pearson r Value p Value 
PRDX2 25 kDa 
Height ,496(*) 0,036 
Dopamine U24 ,522(*) 0,026 
Oximetry ,532(*) 0,028 
PRDX2 20 kDa 
Monomer 
RDI -,540(*) 0,021 
Arousal Index -,498(*) 0,035 
Hb A1C ,500(*) 0,034 
SO2/3 25 kDa Oximetry ,586(*) 0,014 
SO2/3 50 kDa 
Adrenaline U24  -,522(*) 0,026 
Noradrenalin U24  ,501(*) 0,034 
**. Correlation is significant at the 0.01 level (2-tailed).     
*. Correlation is significant at the 0.05 level (2-tailed).     
 
Table Annex IV. 9: Plasma PRDX2 correlations with PSG/Clinical parameters for non-
treated OSA group 
PRDX2 
OSA ALL (N=18) 
Correlation Pearson r Value p Value 
PRDX2 25 kDa Age ,616(**) 0,007 
PRDX2 20 kDa 
Monomer 
ODI -,668(**) 0,002 
Fasting glucose  ,505(*) 0,033 
Homocysteine  -,709(**) 0,001 
RDW  -,659(**) 0,003 
SO2/3 25 kDa no significant correlation observed 
SO2/3 50 kDa RDW  -,526(*) 0,025 
**. Correlation is significant at the 0.01 level (2-tailed).     
*. Correlation is significant at the 0.05 level (2-tailed).     
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Table Annex IV. 10: Plasma PRDX2 correlations with PSG/Clinical parameters for non-
treated OSA group without diabetes 
PRDX2 
OSA W/o DIABETES (N=15) 
Correlation Pearson r Value p Value 
PRDX2 25 kDa 
Age ,628(*) 0,012 
Cholesterol -,516(*) 0,049 
PRDX2 20 kDa 
Monomer 
Homocysteine  -,775(**) 0,001 
RDI -,531(*) 0,042 
ODI -,748(**) 0,001 
RDW -,596(*) 0,019 
SO2/3 25 kDa Age ,529(*) 0,043 
SO2/3 50 kDa 
ODI -,526(*) 0,044 
Platelets, count x 10^9/L ,598(*) 0,019 
**. Correlation is significant at the 0.01 level (2-tailed).     
*. Correlation is significant at the 0.05 level (2-tailed).     
 
Table Annex IV. 11: Plasma PRDX2 correlations with PSG/Clinical parameters for non-
treated diabetic OSA group 
PRDX2 
OSA diabetes (N=3) 
Correlation Pearson r Value p Value 
PRDX2 25 kDa 
Systolic BP 1,000(**) 0,003 
Diastolic BP ,998(*) 0,036 
Triglycerides -,999(*) 0,021 
Dopamine  -,999(*) 0,021 
PRDX2 20 kDa 
Monomer 
Fasting glucose ,999(*) 0,032 
SO2/3 25 kDa 
Height -,999(*) 0,029 
Arousal Index 1,000(**) 0,002 
Hemoglobin ,997(*) 0,047 
Hematocrit 1,000(*) 0,011 
RDW -1,000(**) 0,001 
SO2/3 50 kDa 
WBC count x 10^9/L -,999(*) 0,029 
Platelets, count x 10^9/L -1,000(**) 0,010 
**. Correlation is significant at the 0.01 level (2-tailed).     
*. Correlation is significant at the 0.05 level (2-tailed).     
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Table Annex IV. 12: Plasma PRDX2 correlations with PSG/Clinical parameters for non-
diabetic OSA patients after CPAP treatment 
PRDX2 
CPAP W/o DIABETES (N=15) 
Correlation Pearson r Value p Value 
 Days w/o use -,586(*) 0,022 
PRDX2 25 kDa MCHC  -,590(*) 0,021 
 RDW ,517 0,048 
PRDX2 20 kDa 
Monomer 
RDW ,581(*) 0,023 
P95 ,619(*) 0,014 
SO2/3 25 kDa no significant correlation observed 
SO2/3 50 kDa no significant correlation observed 
**. Correlation is significant at the 0.01 level (2-tailed).     
*. Correlation is significant at the 0.05 level (2-tailed).     
 
Table Annex IV. 13: Plasma PRDX2 correlations with PSG/Clinical parameters for 
diabetic OSA patients after CPAP treatment 
PRDX2 
CPAP DIABETES (N= 3) 
Correlation Pearson r Value p Value 
PRDX2 25 kDa 
RDW ,999(*) 0,026 
Hb A1C -,998(*) 0,041 
PRDX2 20 kDa 
Monomer 
Insulin ,999(*) 0,030 
SO2/3 25 kDa 
Dopamine -,999(*) 0,024 
MCHC -1,000(**) 0,009 
SO2/3 50 kDa Platelets, count x 10^9/L -1,000(**) 0,006 
**. Correlation is significant at the 0.01 level (2-tailed).     
*. Correlation is significant at the 0.05 level (2-tailed).     
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Annex V 
 
Figure Annex V. 1: Example of a membrane colored with Ponceau solution after 
transference. Hemoglobin band was used to normalize areas obtained from final WB 
results of RBC PRDX2 and PRDX SO2/3 quantification using ImageJ software. 
 
 
Figure Annex V. 2: Example of a membrane colored with Ponceau solution after 
transference. Albumin band was used to normalize areas obtained from final WB 
results of Plasma PRDX2 and PRDX SO2/3 quantification using ImageJ software. 
 
